<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for deliberately altering blood pressure in acute stroke - Bath, PMW - 2014 | Cochrane Library</title> <meta content="Interventions for deliberately altering blood pressure in acute stroke - Bath, PMW - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000039.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for deliberately altering blood pressure in acute stroke - Bath, PMW - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000039.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000039.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for deliberately altering blood pressure in acute stroke" name="citation_title"/> <meta content="Philip MW Bath" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="philip.bath@nottingham.ac.uk" name="citation_author_email"/> <meta content="Kailash Krishnan" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD000039.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/10/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000039.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000039.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000039.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Blood Pressure [*drug effects]; Calcium Channel Blockers [*therapeutic use]; Hypertension [drug therapy]; Randomized Controlled Trials as Topic; Risk; Stroke [physiopathology, *prevention &amp; control]; Time‐to‐Treatment [statistics &amp; numerical data]; Vasodilator Agents [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000039.pub3&amp;doi=10.1002/14651858.CD000039.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="STpJR8yz";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000039\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000039\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ko","hr","fr","ja","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000039.pub3",title:"Interventions for deliberately altering blood pressure in acute stroke",firstPublishedDate:"Oct 28, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000039.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000039.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000039.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000039.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000039.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000039.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000039.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000039.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000039.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000039.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9899 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000039.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-sec-0118"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-sec-0029"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-sec-0103"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/appendices#CD000039-sec-0123"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/table_n/CD000039StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/table_n/CD000039StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for deliberately altering blood pressure in acute stroke</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/information#CD000039-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Philip MW Bath</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000039.pub3/information#CD000039-cr-0003">Kailash Krishnan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/information/en#CD000039-sec-0135">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 October 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000039.pub3">https://doi.org/10.1002/14651858.CD000039.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000039-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000039-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000039-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000039-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000039-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000039-abs-0002">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000039-abs-0001" lang="en"> <section id="CD000039-sec-0001"> <h3 class="title" id="CD000039-sec-0001">Background</h3> <p>It is unclear whether blood pressure should be altered actively during the acute phase of stroke. This is an update of a Cochrane review first published in 1997, and previously updated in 2001 and 2008. </p> </section> <section id="CD000039-sec-0002"> <h3 class="title" id="CD000039-sec-0002">Objectives</h3> <p>To assess the clinical effectiveness of altering blood pressure in people with acute stroke, and the effect of different vasoactive drugs on blood pressure in acute stroke. </p> </section> <section id="CD000039-sec-0003"> <h3 class="title" id="CD000039-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (last searched in February 2014), the Cochrane Database of Systematic reviews (CDSR) and the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2014, Issue 2), MEDLINE (Ovid) (1966 to May 2014), EMBASE (Ovid) (1974 to May 2014), Science Citation Index (ISI, Web of Science, 1981 to May 2014) and the Stroke Trials Registry (searched May 2014). </p> </section> <section id="CD000039-sec-0004"> <h3 class="title" id="CD000039-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of interventions that aimed to alter blood pressure compared with control in participants within one week of acute ischaemic or haemorrhagic stroke. </p> </section> <section id="CD000039-sec-0005"> <h3 class="title" id="CD000039-sec-0005">Data collection and analysis</h3> <p>Two review authors independently applied the inclusion criteria, assessed trial quality and extracted data. The review authors cross‐checked data and resolved discrepancies by discussion to reach consensus. We obtained published and unpublished data where available. </p> </section> <section id="CD000039-sec-0006"> <h3 class="title" id="CD000039-sec-0006">Main results</h3> <p>We included 26 trials involving 17,011 participants (8497 participants were assigned active therapy and 8514 participants received placebo/control). Not all trials contributed to each outcome. Most data came from trials that had a wide time window for recruitment; four trials gave treatment within six hours and one trial within eight hours. The trials tested alpha‐2 adrenergic agonists (A2AA), angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor antagonists (ARA), calcium channel blockers (CCBs), nitric oxide (NO) donors, thiazide‐like diuretics, and target‐driven blood pressure lowering. One trial tested phenylephrine. </p> <p>At 24 hours after randomisation oral ACEIs reduced systolic blood pressure (SBP, mean difference (MD) ‐8 mmHg, 95% confidence interval (CI) ‐17 to 1) and diastolic blood pressure (DBP, MD ‐3 mmHg, 95% CI ‐9 to 2), sublingual ACEIs reduced SBP (MD ‐12.00 mm Hg, 95% CI ‐26 to 2) and DBP (MD ‐2, 95%CI ‐10 to 6), oral ARA reduced SBP (MD ‐1 mm Hg, 95% CI ‐3 to 2) and DBP (MD ‐1 mm Hg, 95% CI ‐3 to 1), oral beta blockers reduced SBP (MD ‐14 mm Hg; 95% CI ‐27 to ‐1) and DBP (MD ‐1 mm Hg, 95% CI ‐9 to 7), intravenous (iv) beta blockers reduced SBP (MD ‐5 mm Hg, 95% CI ‐18 to 8) and DBP (‐5 mm Hg, 95% CI ‐13 to 3), oral CCBs reduced SBP (MD ‐13 mmHg, 95% CI ‐43 to 17) and DBP (MD ‐6 mmHg, 95% CI ‐14 to 2), iv CCBs reduced SBP (MD ‐32 mmHg, 95% CI ‐65 to 1) and DBP (MD ‐13, 95% CI ‐31 to 6), NO donors reduced SBP (MD ‐12 mmHg, 95% CI ‐19 to ‐5) and DBP (MD ‐3, 95% CI ‐4 to ‐2) while phenylephrine, non‐significantly increased SBP (MD 21 mmHg, 95% CI ‐13 to 55) and DBP (MD 1 mmHg, 95% CI ‐15 to 16). </p> <p>Blood pressure lowering did not reduce death or dependency either by drug class (OR 0.98, 95% CI 0.92 to 1.05), stroke type (OR 0.98, 95% CI 0.92 to 1.05) or time to treatment (OR 0.98, 95% CI 0.92 to 1.05). Treatment within six hours of stroke appeared effective in reducing death or dependency (OR 0.86, 95% CI 0.76 to 0.99) but not death (OR 0.70, 95% CI 0.38 to 1.26) at the end of the trial. Although death or dependency did not differ between people who continued pre‐stroke antihypertensive treatment versus those who stopped it temporarily (worse outcome with continuing treatment, OR 1.06, 95% CI 0.91 to 1.24), disability scores at the end of the trial were worse in participants randomised to continue treatment (Barthel Index, MD ‐3.2, 95% CI ‐5.8, ‐0.6). </p> </section> <section id="CD000039-sec-0007"> <h3 class="title" id="CD000039-sec-0007">Authors' conclusions</h3> <p>There is insufficient evidence that lowering blood pressure during the acute phase of stroke improves functional outcome. It is reasonable to withhold blood pressure‐lowering drugs until patients are medically and neurologically stable, and have suitable oral or enteral access, after which drugs can than be reintroduced. In people with acute stroke, CCBs, ACEI, ARA, beta blockers and NO donors each lower blood pressure while phenylephrine probably increases blood pressure. Further trials are needed to identify which people are most likely to benefit from early treatment, in particular whether treatment started very early is beneficial. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000039-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000039-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000039-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000039-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000039-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000039-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD000039-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000039-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000039-abs-0006">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000039-abs-0005" lang="en"> <h3>Drug interventions for deliberately altering blood pressure in acute stroke</h3> <p><b>Background:</b> In people who have just had a stroke (a sudden brain attack due to either blockage or rupture of an artery in the brain), very high and very low blood pressures may be harmful. Therefore, drugs that raise low blood pressure or lower high blood pressure might be beneficial. Up to 50% of people admitted with acute stroke are taking blood pressure tablets on hospital admission and it is not clear whether these medications should be continued or discontinued in the acute situation. This review looked at those trials that deliberately altered blood pressure or compared continuing or stopping blood pressure‐lowering tablets taken before stroke. </p> <p><b>Study characteristics:</b> This review is up‐to‐date to May 2014. We included 26 trials involving 17,011 participants: 24 trials assessed lowering blood pressure, one trial tested raising blood pressure, and two trials assessed what to do with drugs taken before stroke. All studies took place in hospitals that were used to treating people with stroke. Not all trials contributed information to all outcomes, and we have used data that were available in publications. </p> <p><b>Key results:</b> There is insufficient evidence to say that lowering blood pressure saves lives or reduces disability in people with acute stroke. Immediately restarting blood pressure‐lowering drugs taken before the stroke may increase disability. </p> <p><b>Conclusion:</b> More research is needed to identify those people who are most likely to benefit from altering blood pressure in acute stroke, the time window in which the treatment is likely to be of benefit, what types of stroke are likely to respond favourably, and the environment in which such treatment may be best given in routine practice. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000039-sec-0118" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000039-sec-0118"></div> <h3 class="title" id="CD000039-sec-0119">Implications for practice</h3> <section id="CD000039-sec-0119"> <p>The lack of definitive results for blood pressure lowering, and very limited data for raising blood pressure, mean that no firm recommendations can be made. </p> <p>There is no evidence to support the routine policy of immediately continuing prestroke antihypertensive drugs; treatment may be re‐started once patients have stabilised medically and neurologically, and once safe feeding or enteral access is available. </p> <p>The very limited data related to blood pressure elevation mean that no recommendations can be made. </p> </section> <h3 class="title" id="CD000039-sec-0120">Implications for research</h3> <section id="CD000039-sec-0120"> <p>Large randomised controlled trials (RCTs) of blood pressure lowering are needed to:</p> <p> <ul id="CD000039-list-0021"> <li> <p>test the effect of ultra‐acute/pre‐hospital lowering of blood pressure in RCTs;</p> </li> <li> <p>test the effect of hyper‐acute/hospital lowering of blood pressure in RCTs. Two trials are important examples of ongoing studies (<a href="./references#CD000039-bbs2-0100" title="Qureshi , AI . Antihypertensive treatment of acute cerebral hemorrhage (ATACH): rationale and design. Neurocritical Care2007;6:56‐66. ">ATACH‐2 2011</a>; <a href="./references#CD000039-bbs2-0101" title="AndersonC , ENCHANTED investigators. Enhanced control of hypertension and thrombolysis stroke study: a multicentre randomised trial. Current Controlled Trials2011. [ISRCTN82387104] ">ENCHANTED 2011</a>); </p> </li> <li> <p>determine the effects on long‐term survival (≥ one year);</p> </li> <li> <p>determine the effects on quality of life and cost‐effectiveness.</p> </li> </ul> </p> <p>An individual patient data (IPD) meta‐analysis is required to:</p> <p> <ul id="CD000039-list-0022"> <li> <p>identify subgroups of patients who are likely to benefit or be harmed, e.g. by age, sex, race‐ethnicity group, baseline blood pressure, history of hypertension, stroke type (ischaemic stroke, ICH); </p> </li> <li> <p>identify what type of treatment is required, e.g. drug class, route, dose of administration.</p> </li> </ul> </p> <p>The ongoing 'Blood pressure in Acute Stroke Collaboration' is performing an IPD meta‐analysis and includes many of the quoted trials. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000039-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000039-sec-0029"></div> <section id="CD000039-sec-0030"> <h3 class="title" id="CD000039-sec-0030">Description of the condition</h3> <p>Stroke is the third most common cause of death and the most common cause of disability in the western world. Acute stroke, whether due to infarction or haemorrhage, is associated with high blood pressure in 75% of patients, of whom 50% have a previous history of high blood pressure (<a href="./references#CD000039-bbs2-0117" title="BrittonM , CarlssonA , deFaireU . Blood pressure course in patients with acute stroke and matched controls. Stroke1986;17:861‐4. ">Britton 1986</a>; <a href="./references#CD000039-bbs2-0141" title="OppenheimerS , HachinskiV . Complications of acute stroke. Lancet1992;339:721‐4. ">Oppenheimer 1992</a>). After a stroke, blood pressure falls in most patients over a week although a third of patients remain hypertensive (<a href="./references#CD000039-bbs2-0155" title="WallaceJD , LevyLL . Blood pressure after stroke. JAMA1981;246:2177‐80. ">Wallace 1981</a>; <a href="./references#CD000039-bbs2-0117" title="BrittonM , CarlssonA , deFaireU . Blood pressure course in patients with acute stroke and matched controls. Stroke1986;17:861‐4. ">Britton 1986</a>; <a href="./references#CD000039-bbs2-0129" title="HarperG , CastledenCM , PotterJF . Factors effecting changes in blood pressure after acute stroke. Stroke1994;25:1726‐9. ">Harper 1994</a>). A number of small studies have assessed the relationship between blood pressure (<a href="./references#CD000039-bbs2-0138" title="MarshallJ , ShawDA . The natural history of cerebrovascular disease. British Medical Journal1959;i:1614‐7. ">Marshall 1959</a>; <a href="./references#CD000039-bbs2-0104" title="AdamsGF . Prospects for patients with strokes, with special reference to the hypertensive hemiplegic. British Medical Journal1965;ii:253‐9. ">Adams 1965</a>; <a href="./references#CD000039-bbs2-0123" title="DrollerH . The outlook in hemiplegia. Geriatrics1965;20:630‐6. ">Droller 1965</a>; <a href="./references#CD000039-bbs2-0115" title="BourestomNC . Predictors of long term recovery in cerebrovascular disease. Archives of Physical Medicine and Rehabilitation1967;48:415‐9. ">Bourestom 1967</a>; <a href="./references#CD000039-bbs2-0137" title="MarquarsdenJ . The natural history of acute cerebrovascular disease: a retrospective study of 769 patients. Acta Neurologica Scandinavica1969;45 Suppl 38:118‐24. ">Marquarsden 1969</a>; <a href="./references#CD000039-bbs2-0119" title="CarlbergB , AsplundK , HaggE . The prognostic value of admission blood pressure in patients with acute stroke. Stroke1993;24:1372‐5. ">Carlberg 1993</a>) and outcome. A meta‐analysis of these studies found that elevated blood pressure was associated with a poor outcome (<a href="./references#CD000039-bbs2-0156" title="WillmotM , Leonardi‐BeeJ , BathPMW . High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension2004;43:18‐24. ">Willmot 2004</a>). Data from 17,398 participants in the International Stroke Trial identified a U‐shaped relationship such that both low and high blood pressure were associated independently with increased early death and later death or dependency (<a href="./references#CD000039-bbs2-0136" title="Leonardi‐BeeJ , BathPMW , PhillipsSJ , SandercockPAG . Blood pressure and clinical outcomes in the International Stroke Trial. Stroke2002;33:1315‐20. ">Leonardi‐Bee 2002</a>), a finding that has been replicated by others (<a href="./references#CD000039-bbs2-0120" title="CastilloJ , LeiraR , GarcíaMM , SerenaJ , BlancoM , DávalosA . Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke2004;35(2):520‐6. ">Castillo 2004</a>; <a href="./references#CD000039-bbs2-0153" title="VemmosKN , TsivgoulisG , SpengosK , ZakopoulosN , SynetosA , ManiosE , et al. U‐shaped relationship between mortality and admission blood pressure in patients with acute stroke. Journal of Internal Medicine2004;255:257‐65. ">Vemmos 2004</a>). High blood pressure is also associated with an increased early recurrence of stroke (<a href="./references#CD000039-bbs2-0136" title="Leonardi‐BeeJ , BathPMW , PhillipsSJ , SandercockPAG . Blood pressure and clinical outcomes in the International Stroke Trial. Stroke2002;33:1315‐20. ">Leonardi‐Bee 2002</a>; <a href="./references#CD000039-bbs2-0151" title="SpriggN , GrayLJ , BathPMW , BoysenG , DeDeynPP , FrissP , et al. Relationship between outcome and baseline blood pressure and other haemodynamic measures in acute ischaemic stroke: data from the TAIST trial. Journal of Hypertension2006;24(7):1413‐8. ">Sprigg 2006</a>). </p> <p>The mechanisms underlying high blood pressure in stroke are complex but pre‐existing hypertension, hospitalisation stress, activation of the sympathetic renin‐angiotensin‐aldosterone, cortisol and natriuretic peptide neuroendocrine systems, and the Cushing reflex (raised blood pressure secondary to raised intracranial pressure) all contribute (<a href="./references#CD000039-bbs2-0139" title="MyersM , NorrisJ , HachinskiV , WeingertM , SoleM . Cardiac sequelae of acute stroke. Stroke1982;13:838‐42. ">Myers 1982</a>). In ischaemic stroke, high blood pressure also appears to adversely affect outcome through increasing the risk of cerebral oedema, but not haemorrhagic transformation (<a href="./references#CD000039-bbs2-0136" title="Leonardi‐BeeJ , BathPMW , PhillipsSJ , SandercockPAG . Blood pressure and clinical outcomes in the International Stroke Trial. Stroke2002;33:1315‐20. ">Leonardi‐Bee 2002</a>). Haematoma expansion is related to high blood pressure in people with intracerebral haemorrhage (ICH) although this relationship may be confounded by stroke severity and time to presentation (<a href="./references#CD000039-bbs2-0126" title="FujiiY , TanakaR , TakeuchiS , KoikeT , MinakawaT , SasakiO . Hematoma enlargement in spontaneous intracerebral hemorrhage. Journal of Neurosurgery1994;80:51‐7. ">Fujii 1994</a>; <a href="./references#CD000039-bbs2-0134" title="KazuiS , MinematsuK , YamamotoH , SawadaT , YamaguchiT . Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke1997;28:2370‐5. ">Kazui 1997</a>; <a href="./references#CD000039-bbs2-0127" title="FujiiY , TakeuchiS , SasakiO , MinakawaT , TanakaR . Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke1998;29:1160‐6. ">Fujii 1998</a>; <a href="./references#CD000039-bbs2-0111" title="BathP , ChalmersJ , PowersW , BeilinL , DavisS , LenfantC , et al. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. Journal of Hypertension2003;21(4):665‐72. ">Bath 2003</a>). </p> </section> <section id="CD000039-sec-0031"> <h3 class="title" id="CD000039-sec-0031">Description of the intervention</h3> <p>Although debated more than 29 years ago, it still remains unclear whether high blood pressure should (<a href="./references#CD000039-bbs2-0149" title="SpenceJD , delMaestroRF . Hypertension in acute ischaemic strokes. Treat. Archives of Neurology1985;42:1000‐2. ">Spence 1985</a>) or should not (<a href="./references#CD000039-bbs2-0157" title="YatsuFM , ZivinJ . Hypertension in acute ischaemic strokes. Not to treat. Archives of Neurology1985;42:999‐1000. ">Yatsu 1985</a>) be treated acutely following stroke. Recent guidelines recommend that acute lowering of blood pressure should be delayed for several days or even weeks unless blood pressure is greater than 220/120 mmHg, blood pressure is greater than 200/100 mmHg with end organ involvement (hypertensive encephalopathy, aortic dissection, cardiac ischaemia, pulmonary oedema, acute renal failure), or blood pressure is greater than 200/120 mmHg with primary ICH, are present (<a href="./references#CD000039-bbs2-0140" title="O'ConnellJE , GrayCS . Treating hypertension after stroke. BMJ1994;308:1523‐4. ">O'Connell 1994</a>; <a href="./references#CD000039-bbs2-0124" title="ToniD , ChamorroA , KasteM , LeesK , WahlgrenNG , HackeW . Acute treatment of ischaemic stroke. Cerebrovascular Diseases2004;17 Suppl 2:30‐46. ">EUSI 2004</a>; <a href="./references#CD000039-bbs2-0105" title="MorgensternLB , Hemphill IIIJC , AndersonC , BeckerC , BroderickJP , ConnollyES , et al. Guidelines for the management of spontaneous intracerebral haemorrhage. Stroke2010;41:2108‐29. ">AHA‐HS 2010</a>; <a href="./references#CD000039-bbs2-0145" title="Intercollegiate Stroke Working Party. National Clinical Guideline for Stroke. 4th Edition. London: Royal College of Physicians, 2012. ">RCP 2012</a>; <a href="./references#CD000039-bbs2-0106" title="JauchEC , SaverJL , Adams JrHP , BrunoA , ConnorsB , DemaerschalkBM , et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke2013;44:870‐947. ">AHA‐IS 2013</a>). Though the evidence is weaker, guidelines now recommend that patients who have elevated blood pressure and are otherwise eligible for treatment with recombinant tissue plasminogen activator may have their blood pressure lowered so that systolic blood pressure (SBP) is less than or equal to 185 mmHg and diastolic blood pressure (DBP) is less than or equal to 110 mmHg before thrombolysis using intravenous labetalol, nitroprusside or nicardipine and it should be maintained below 180/105 mmHg for at least the first 24 hours after therapy (<a href="./references#CD000039-bbs2-0106" title="JauchEC , SaverJL , Adams JrHP , BrunoA , ConnorsB , DemaerschalkBM , et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke2013;44:870‐947. ">AHA‐IS 2013</a>). Unfortunately, such guidelines are inconsistent and are based on theoretical arguments and individual case reports, and not on the results of systematic overviews or large intervention trials of blood pressure manipulation in acute stroke. Nevertheless, a number of case reports and series have suggested that active lowering of blood pressure in people with primary intracranial haemorrhage and ischaemic stroke may improve (<a href="./references#CD000039-bbs2-0122" title="DandapaniB , SuzukiS , KelleyRE , Reyes‐IglesiasY , DuncanRC . Relation between blood pressure and outcome in intracerebral hemorrhage. Stroke1995;26:21‐4. ">Dandapani 1995</a>; <a href="./references#CD000039-bbs2-0121" title="ChamorroA , VilaN , AscasoC , ElicesE , SchonewilleW , BlancR . Blood pressure and functional recovery in acute ischemic stroke. Stroke1998;29:1850‐3. ">Chamorro 1998</a>) or worsen (<a href="./references#CD000039-bbs2-0128" title="GrahamDI . Ischaemic stroke brain damage after cerebral perfusion failure after treatment of severe hypertension. British Medical Journal1975;4:739. ">Graham 1975</a>; <a href="./references#CD000039-bbs2-0116" title="BrittonM , deFaireU , HelmersC . Hazards of therapy for excessive hypertension in acute stroke. Acta Medica Scandinavica1980;207:253‐7. ">Britton 1980</a>; <a href="./references#CD000039-bbs2-0125" title="FischbergGM , LozanoE , RajamaniK , AmerisoS , FisherMJ . Stroke precipitated by moderate blood pressure reduction. Journal of Emergency Medicine2000;19:339‐46. ">Fischberg 2000</a>) outcome. </p> <p>Low blood pressure is not common in acute stroke but it, like high blood pressure, is associated with a poor outcome (<a href="./references#CD000039-bbs2-0136" title="Leonardi‐BeeJ , BathPMW , PhillipsSJ , SandercockPAG . Blood pressure and clinical outcomes in the International Stroke Trial. Stroke2002;33:1315‐20. ">Leonardi‐Bee 2002</a>). Possible reasons for low blood pressure include potentially reversible conditions such as hypovolaemia, sepsis, impaired cardiac output secondary to cardiac failure, arrhythmias or cardiac ischaemia, and aortic dissection (<a href="./references#CD000039-bbs2-0150" title="SpriggN , BathPMW . Management of blood pressure in acute stroke. Practical Neurology2005;5:218‐23. ">Sprigg 2005</a>). Guidelines recommend that causes of hypotension in the setting of acute stroke should be sought with the view to correcting reversible causes such as hypovolaemia and cardiac arrhythmias (<a href="./references#CD000039-bbs2-0106" title="JauchEC , SaverJL , Adams JrHP , BrunoA , ConnorsB , DemaerschalkBM , et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke2013;44:870‐947. ">AHA‐IS 2013</a>). Since cerebral autoregulation is lost following stroke (<a href="./references#CD000039-bbs2-0152" title="StrandgaardS , OlesenJ , SkinhojE , LassenNA . Autoregulation of brain circulation in severe arterial hypertension. British Medical Journal1973;3:507‐10. ">Strandgaard 1973</a>; <a href="./references#CD000039-bbs2-0118" title="BurkeAM , YounkinD , GordonJ , GoldbergH , GrahamT , KushnerM , et al. Changes in cerebral blood flow and recovery from acute stroke. Stroke1986;17:173‐8. ">Burke 1986</a>; <a href="./references#CD000039-bbs2-0142" title="PaulsonOB , StrandgaardS , EdvinssonL . Cerebral autoregulation. Cerebrovascular and Brain Metabolism Reviews1990;2:161‐92. ">Paulson 1990</a>), such that cerebral blood flow becomes dependent on systemic blood pressure, some researchers have hypothesised that blood pressure should be increased to improve cerebral perfusion (<a href="./references#CD000039-bbs2-0148" title="SandercockP , WillemsH . Medical treatment of acute ischaemic stroke. Lancet1992;339:537‐9. ">Sandercock 1992</a>) and a case series (<a href="./references#CD000039-bbs2-0083" title="RordorfG , CramerSC , EfirdJT , SchwammLH , BuonannoF , KoroshetzWJ . Pharmacological elevation of blood pressure in acute stroke. Clinical effects and safety. Stroke1997;28(11):2133‐8. ">Rordorf 1997</a>) and a pilot randomised trial of phenylephrine (<a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>) reporting this approach have been published. </p> </section> <section id="CD000039-sec-0032"> <h3 class="title" id="CD000039-sec-0032">How the intervention might work</h3> <p>Although the different drugs assessed work in a variety of ways, all lower (or elevate ‐ phenylephrine) blood pressure. </p> </section> <section id="CD000039-sec-0033"> <h3 class="title" id="CD000039-sec-0033">Why it is important to do this review</h3> <p>We are reviewing this topic in three parts (<a href="./references#CD000039-bbs2-0108" title="BathFJ , BathPMW . What is the correct management of blood pressure in acute stroke? The Blood pressure in Acute Stroke Collaboration. Cerebrovascular Diseases1997;7:205‐13. ">Bath 1997</a>). </p> <section id="CD000039-sec-0034"> <h4 class="title">Part 1: this review</h4> <p>Assessment of trials in which the primary aim of the intervention was to alter blood pressure in people with acute stroke with the aim of improving clinical outcome. </p> <p>A Cochrane review of blood pressure intervention in stroke published in 2001 (<a href="./references#CD000039-bbs2-0158" title="Blood Pressure in Acute Stroke Collaboration. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database of Systematic Reviews2001, Issue 3. [DOI: 10.1002/14651858.CD000039] ">BASC 2001</a>) updated the original review published in 1997. It was again updated in 2008 to include more information from 13 trials published between 2003 and 2008 including a total of 1153 participants (<a href="./references#CD000039-bbs2-0159" title="GeeganageC , BathPMW . Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD000039.pub2] ">BASC 2009</a>). With a relatively small amount of data, there was insufficient evidence to evaluate the effect of altering blood pressure during the acute phase of stroke. </p> <p>The present review includes all new trials completed and published since 2008. The total number of participants is now 17,011, a 14‐fold increase since the review in 1997 and 2008. Although many of the data are from trials testing blood pressure alteration in the acute phase (≤ 48 hours), some recent trials have examined specific questions such as lowering blood pressure in ICH (<a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>), with angiotensin receptor antagonists (<a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>), or glyceryl nitrate (<a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>) or in the pre‐hospital setting (<a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>). Furthermore, two trials (<a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>) have investigated whether to continue or stop temporarily pre‐stroke antihypertensive therapy. This systematic review includes these data and provides up‐to‐date evidence. </p> </section> <section id="CD000039-sec-0035"> <h4 class="title">Part 2: vasoactive drugs for acute stroke</h4> <p>Assessment of trials where vasoactive drugs were administered to people with acute stroke and where clinical outcome was measured. Drugs include: alpha receptor antagonists, angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor inhibitors (ARA), beta receptor antagonists, calcium channel blockers (CCB), diuretics, magnesium, naftidrofuryl, nitric oxide donors (nitrates), papaverine, pentoxifylline, prostacyclin, serotonin receptor antagonists, sympathomimetics, theophylline (and mimetics), thromboxane A2 antagonists, vinpocetine, and their derivatives. Aggregated patient data are analysed separately for drugs which lower and elevate blood pressure (<a href="./references#CD000039-bbs2-0107" title="Blood Pressure in Acute Stroke Collaboration. Vasoactive drugs for acute stroke. Cochrane Database of Systematic Reviews2000, Issue 4. [DOI: 10.1002/14651858.CD002839] ">BASC 2000</a>). Work on this analysis is ongoing. </p> </section> <section id="CD000039-sec-0036"> <h4 class="title">Part 3: analysis of individual patient data from the trials identified in parts 1 and 2 </h4> <p>Work on this analysis is ongoing through the international Blood pressure in Acute Stroke Collaboration. In brief, individual patient data from the trials included in Part 1 and Part 2 are being collated with the intention of extending analyses, particularly in subgroups of participants and interventions. </p> </section> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000039-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000039-sec-0037"></div> <p>To assess the clinical effectiveness of altering blood pressure in people with acute stroke, and the effect of different vasoactive drugs on blood pressure in acute stroke. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000039-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000039-sec-0038"></div> <section id="CD000039-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000039-sec-0040"> <h4 class="title">Types of studies</h4> <p>Published and unpublished randomised controlled trials (RCTs) of vasoactive drugs in acute ischaemic stroke or acute intracerebral haemorrhage (ICH) where the aim of the trial was to alter blood pressure, and drug therapy was initiated within one week of stroke onset. We excluded uncontrolled studies, confounded controlled studies where two or more active interventions were compared, and studies of people with subarachnoid haemorrhage. </p> </section> <section id="CD000039-sec-0041"> <h4 class="title">Types of participants</h4> <p>Adults (age 18 or older) of either sex with acute ischaemic stroke or ICH who were eligible for randomisation to either active treatment, or placebo or open control. </p> </section> <section id="CD000039-sec-0042"> <h4 class="title">Types of interventions</h4> <p>We sought RCTs evaluating single or multiple agents of deliberate blood pressure lowering or elevation in acute stroke, regardless of dosage or route of treatment, compared against placebo or open control. We also included trials with two groups receiving different doses of the same BP lowering agent, and studies assessing effects of continuing or stopping pre‐existing antihypertensive treatment. </p> </section> <section id="CD000039-sec-0043"> <h4 class="title">Types of outcome measures</h4> <section id="CD000039-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD000039-list-0001"> <li> <p>Combined death or disability/dependency at end of trial (≥ one month after stroke). We defined death or dependency as the modified Rankin Scale (mRS) &gt; 2 (or &gt; 3 as available). </p> </li> </ul> </p> </section> <section id="CD000039-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD000039-list-0002"> <li> <p>Blood pressure when first measured after randomisation.</p> </li> <li> <p>Early case fatality (&lt; one month).</p> </li> <li> <p>Late case fatality (≥ one month).</p> </li> <li> <p>Early neurological deterioration (&lt; one month). As there is no consensus on how early neurological deterioration should be standardised, we used the trial‐specific definition as a decrease in the Scandinavian Stroke Scale (SSS) of &gt; 5 points or a decrease in consciousness part of the SSS by &gt; 2 points (<a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>), increase in the National Institutes of Health Stroke Scale (NIHSS) of 2 (<a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>) or more (<a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>) or decline of 2 or more points in Glasgow Coma Scale (GCS) (<a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>). </p> </li> <li> <p>Late disability or dependency (Barthel Index ≥ one month).</p> </li> <li> <p>Baseline and on‐treatment blood pressure and heart rate.</p> </li> </ul> </p> </section> </section> </section> <section id="CD000039-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <p>See the 'Specialized register' section in the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/STROKE/frame.html" target="_blank">Cochrane Stroke Group</a> module. Our methods comprised electronic searches and assessment of studies referenced in published systematic and non‐systematic reviews. We applied no language restrictions. </p> <section id="CD000039-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Stroke Group Trials Register, (last searched by the Managing Editor in February 2014), the Cochrane Database of Systematic reviews (CDSR) and the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2014, Issue 2), MEDLINE (Ovid) (1966 to May 2014) (<a href="./appendices#CD000039-sec-0124">Appendix 1</a>), EMBASE (Ovid) (1974 to May 2014) (<a href="./appendices#CD000039-sec-0125">Appendix 2</a>), Science Citation Index (ISI, Web of Science, 1981 to May 2014) (<a href="./appendices#CD000039-sec-0126">Appendix 3</a>) and the Stroke Trials Registry (<a href="http://www.strokecenter.org/trials/" target="_blank">www.strokecenter.org/trials/</a>) (searched May 2014). </p> </section> <section id="CD000039-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We searched reviews of acute stroke relating to drugs that may alter blood pressure, including: calcium channel blockers (CCBs) (<a href="./references#CD000039-bbs2-0132" title="HornJ , LimburgM . Calcium antagonists for ischemic stroke: a systematic review. Stroke2001;32:570‐6. ">Horn 2001</a>), nitric oxide (<a href="./references#CD000039-bbs2-0110" title="BathPMW , WillmotM , Leonardi‐BeeJ , Bath‐HextallFJ . Nitric oxide donor donors (nitrates), L‐arginine, or nitric oxide synthase inhibitors for acute stroke. Cochrane Database of Systematic Reviews2002, Issue 4. [DOI: 10.1002/14651858.CD000398] ">Bath 2002</a>), pentoxifylline (<a href="./references#CD000039-bbs2-0112" title="BathPMW , Bath‐HextallFJ . Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD000162.pub2] ">Bath 2004a</a>) and prostacyclin (<a href="./references#CD000039-bbs2-0113" title="BathPMW . Prostacyclin and analogues for acute ischaemic stroke. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD000177.pub2] ">Bath 2004b</a>). In addition, we searched reference lists of included trials and relevant papers. We contacted principal investigators and researchers when we required additional information. For a previous version of this review (<a href="./references#CD000039-bbs2-0158" title="Blood Pressure in Acute Stroke Collaboration. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database of Systematic Reviews2001, Issue 3. [DOI: 10.1002/14651858.CD000039] ">BASC 2001</a>), we contacted the following pharmaceutical companies: Bayer (nimodipine), Napp (pentoxifylline), Novartis (isradipine), Lipha Sante (naftidrofuryl), Hoffmann la Roche (N‐methyl‐D‐aspartate), Hoechst (flunarizine) and UCB Pharma (piracetam). </p> </section> </section> <section id="CD000039-sec-0049"> <h3 class="title" id="CD000039-sec-0049">Data collection and analysis</h3> <p>We extracted data using a standard proforma; KK entered data into Review Manager (<a href="./references#CD000039-bbs2-0146" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) and PB checked the data. </p> <section id="CD000039-sec-0050"> <h4 class="title">Selection of studies</h4> <p>For this update, one review author (KK) screened the records obtained from the electronic searches and excluded obviously irrelevant studies. We obtained the full paper copy of the remaining studies and both review authors (KK and PB) selected trials for inclusion criteria detailed previously. We resolved any disagreements by discussion. </p> </section> <section id="CD000039-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>We extracted data from published and unpublished material where available. We recorded information on the method of randomisation, concealment of allocation, blinding of treatment administration, analysis (intention‐to‐treat, efficacy analysis), stroke type (ischaemia, haemorrhage, or mixed), drug dose, route of administration (oral, sublingual, intravenous, transdermal) and timing, blood pressure and heart rate before and during treatment, numbers of deaths, functional disability, quality of life, and length of stay. </p> </section> <section id="CD000039-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the methodological quality of the trials using the following criteria.</p> <p> <ul id="CD000039-list-0003"> <li> <p>Method of randomisation.</p> </li> <li> <p>Balance of prognostic factors.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of treatment administration.</p> </li> <li> <p>Intention‐to‐treat analysis.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Follow‐up.</p> </li> </ul> </p> <p>We used the quality criteria to derive an overall assessment bias score as 'low risk' (all criteria met), moderate risk (one or more criteria unclear) and high risk (one or more criteria absent) (<a href="./references#CD000039-bbs2-0130" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD000039-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the weighted estimate of the typical treatment effect across trials using RevMan 5 (<a href="./references#CD000039-bbs2-0146" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>), odds ratios (OR) using the Mantel‐Haenszel random‐effects model for binary data, and mean difference (MD) using the inverse variance method for continuous data, each with 95% confidence intervals (CI). </p> </section> <section id="CD000039-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>The primary outcome was based on the modified Rankin Scale (mRS 0 to 6, where death = 6) assessed using the binary outcome of combined death or dependency (mRS &gt; 1 or &gt; 2 depending on trial definition). The Barthel Index (BI) (disability measure of activities of daily living) was also assessed (BI 100 to ‐5, where death = ‐5). Where functional outcome was not assessed, we excluded the trial from analysis of functional outcome. </p> </section> <section id="CD000039-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to collect missing data from trial investigators. In instances where on‐treatment blood pressure data were not provided or could not be obtained from study authors, we obtained data (mean, SD) from graphs in the trial publication; where the SD was not presented graphically, we used baseline data, a conservative strategy. We excluded trials from individual analyses when summary data were omitted in the trial publication. </p> </section> <section id="CD000039-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between RCTs' results using the I<sup>2</sup> statistic based on the DerSimonian‐Laird formula. </p> </section> <section id="CD000039-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>We examined reporting bias using funnel plots (<a href="#CD000039-fig-0001">Figure 1</a>; <a href="#CD000039-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD000039-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Blood pressure lowering therapy in acute stroke, outcome: 1.1 Death or dependency, end of trial by intervention." data-id="CD000039-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Blood pressure lowering therapy in acute stroke, outcome: 1.1 Death or dependency, end of trial by intervention. </p> </div> </div> </div> <div class="figure" id="CD000039-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Blood pressure lowering therapy in acute stroke, outcome: 1.23 SBP, first after randomisation, by intervention." data-id="CD000039-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Blood pressure lowering therapy in acute stroke, outcome: 1.23 SBP, first after randomisation, by intervention. </p> </div> </div> </div> </section> <section id="CD000039-sec-0058"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analysis using RevMan (<a href="./references#CD000039-bbs2-0146" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). We reported outcomes as ORs with 95% CIs for dichotomous data, and MD with 95% CI for continuous data. We used a random‐effects model to analyse individual results regardless of whether there was heterogeneity or not; this is a conservative strategy and takes account that the trials had heterogenous designs and participant populations. </p> </section> <section id="CD000039-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We assessed the primary outcomes in the following pre‐specified subgroups.</p> <p> <ul id="CD000039-list-0004"> <li> <p>Class or type of intervention.</p> </li> <li> <p>Type of stroke: ischaemic stroke or ICH.</p> </li> <li> <p>Stroke location: cortical or subcortical ischaemic stroke; deep or superficial ICH. (The definition of deep haemorrhage was not defined in all the trials and we therefore used the data as given in the trials.) </p> </li> <li> <p>Timing of intervention: ultra‐acute (≤ four hours) and pre‐hospital, hyper‐acute (≤ six hours) and in hospital, acute (≤ 48 hours), sub‐acute (≤ 168 hours). </p> </li> </ul> </p> <p>We considered an I<sup>2</sup> greater than 50% to infer significant heterogeneity. If significant heterogeneity was present, we looked for potential causes, e.g. differences in trial design and study participants. </p> </section> <section id="CD000039-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We based the analyses on all trials. We did not perform any sensitivity analyses.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000039-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000039-sec-0061"></div> <section id="CD000039-sec-0062"> <h3 class="title">Description of studies</h3> <p>The 26 included trials are summarised in <a href="./references#CD000039-sec-0141" title="">Characteristics of included studies</a>, including details on baseline characteristics (<a href="#CD000039-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD000039-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Results of database search" data-id="CD000039-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Results of database search</p> </div> </div> </div> <section id="CD000039-sec-0063"> <h4 class="title">Results of the search</h4> <p>The quantity of outcome data varied between studies:</p> <p> <ul id="CD000039-list-0005"> <li> <p>outcomes not universally collected;</p> </li> <li> <p>some data still to be published.;</p> </li> <li> <p>'raw data' available by personal communication.</p> </li> </ul> </p> <p>If a trial used more than one dose of a particular drug then the trial identifier is written as author followed by year and dose of the drug. Referencing the whole trial was given by author and year. For example the Fagan 1988 trial comprises: (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>; <a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>). </p> </section> <section id="CD000039-sec-0064"> <h4 class="title">Included studies</h4> <p>We identified 26 trials that fulfilled the inclusion criteria (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). Three trials compared more than one drug against the control group (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>) and two studies compared different doses (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>). </p> <p>We obtained trial protocols and group data from published material for the following studies (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>), whilst individual patient data were provided by seven sets of authors (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). We obtained unpublished SBP, DBP and heart rate data for active and control groups by contacting the authors for three trials (<a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>). </p> <p>A variety of strategies and drug classes were used to lower blood pressure.</p> <p> <ul id="CD000039-list-0006"> <li> <p>Alpha‐2‐adrenoceptor agonist, oral centrally‐acting (clonidine: two participants): one trial (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>). </p> </li> <li> <p>Angiotensin converting enzyme‐inhibitor (ACE‐I) (captopril, perindopril or lisinopril: 152 participants): five trials (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>). </p> </li> <li> <p>Angiotensin receptor antagonist (ARA), oral (candesartan or telmisartan: 4190 participants): six trials (<a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>). </p> </li> </ul> <ul id="CD000039-list-0007"> <li> <p>Beta‐receptor antagonist (ß‐RA) (labetalol: 56 participants): one trial (<a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>). </p> </li> <li> <p>Calcium channel blocker (CCB) (nimodipine or nicardipine: 75 participants): three trials (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>). </p> </li> <li> <p>Diuretic, oral thiazide‐like (bendrofluazide: 18 participants): one trial (<a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>). </p> </li> <li> <p>Nitric oxide (NO) donor (transdermal glyceryl trinitrate (GTN): 4197 participants): five trials (<a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> <li> <p>Intensive versus guideline blood pressure targets (7421 participants): five trials (<a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>). </p> </li> <li> <p>Continue versus stop pre‐stroke antihypertensive drugs (2860 participants): two trials (<a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> </ul> </p> <p>One strategy was used to raise blood pressure.</p> <p> <ul id="CD000039-list-0008"> <li> <p>Sympathomimetic, intravenous (phenylephrine: nine participants): one trial (<a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>). </p> </li> </ul> </p> <p>The trials recruited participants with only ischaemic stroke, mixed stroke (ischaemic stroke and ICH), or only ICH. </p> <p> <ul id="CD000039-list-0009"> <li> <p>Ischaemic stroke: 12 trials (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>; <a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>). In the Fagan study (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>; <a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>) participants were recruited with presumed ischaemic stroke based on history and neurological examination. </p> </li> <li> <p>Mixed stroke: 10 trials (<a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> <li> <p>ICH: four trials (<a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>). </p> </li> </ul> </p> <p>Trials recruited participants at different time frames after stroke:</p> <p> <ul id="CD000039-list-0010"> <li> <p>Ulta‐acute (&lt; four hours of onset)/pre‐hospital: two trials (<a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>). </p> </li> <li> <p>Hyper‐acute (&lt; six hours)/hospital: two trials (<a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>). </p> </li> <li> <p>Acute (&lt; 48 hours): 11 trials (<a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> <li> <p>Sub‐acute (&lt; 168 hours): 10 trials (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>). </p> </li> <li> <p>Timing unclear: one trial (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>). </p> </li> </ul> </p> <p>Trials variously defined enrolment blood pressure levels.</p> <p> <ul id="CD000039-list-0011"> <li> <p>Hypertension (SBP &gt; 120 to 170 and ≤ 220 mm Hg): 21 trials (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> <li> <p>Normotension (systolic BP &lt; 140 mmHg): two trials (<a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>). </p> </li> </ul> <ul id="CD000039-list-0012"> <li> <p>No BP criteria: three trials (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>). </p> </li> </ul> </p> <p>Trials treated participants for varying lengths of time.</p> <p> <ul id="CD000039-list-0013"> <li> <p>For one day: one trial (<a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>). </p> </li> <li> <p>For up to two days: three trials (<a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>; <a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>). </p> </li> <li> <p>For up to three days: one trial (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>). </p> </li> <li> <p>For seven to 12 days: 13 trials (<a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> <li> <p>For 14 days: five trials (<a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>). </p> </li> <li> <p>For 21 days: one trial (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>). </p> </li> <li> <p>For 28 days: one trial (<a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>). </p> </li> <li> <p>For three months: one trial (<a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>). </p> </li> <li> <p>For up to 2.5 years: one trial (<a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>); outcomes at one to three months are used and longer‐term follow‐up data are ignored. </p> </li> </ul> </p> <p>The trials recruited from one or more centres.</p> <p> <ul id="CD000039-list-0014"> <li> <p>Single centre: 14 trials (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>). </p> </li> <li> <p>Multicentre: 12 trials (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>; <a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> </ul> </p> <p>A total of 17,011 participants received placebo or control treatment across the studies. Several trials compared two or more active treatment groups (8497 participants) with one control group (8512 participants) (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>). </p> <p>One study reported on 19 participants from a larger RCT (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>); further information on the main study is not available. </p> <p>One trial was performed in two stages: this review includes the first phase, a double‐blind comparison of candesartan versus placebo (<a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>), and excludes the second open‐label comparison of candesartan and an ACE‐I. </p> <p>One study expressly included patients with either ICH, who were given intravenous nimodipine (treatment: eight participants; placebo: three participants), or ischaemic stroke, who were given oral nimodipine (treatment: 38 participants; placebo: 39 participants) (<a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>); 10 participants (treatment: two participants; placebo: eight participants) treated with antihypertensive agents for malignant hypertension, and two participants treated with intravenous nimodipine for subarachnoid haemorrhage were excluded. </p> <p>Data from two trials were only available from published abstracts (<a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>). </p> <section id="CD000039-sec-0065"> <h5 class="title">Blood pressure measurements</h5> <p>Sixteen studies reported the method by which blood pressure was measured, including equipment (manufacturer, model) and patient posture (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). The Fagan trial only reported the average blood pressure measurements at, and for one hour after, morning dosing over seven days of treatment (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>); in the absence of individual patient data, it is not possible to determine the blood pressure at selected time points during treatment. Furthermore, this trial co‐administered beta blockers to some participants, although these were always given at least two hours before or after nimodipine. In <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>, during the first three days blood pressure measurements were performed by nurses as part of routine clinical care; on day seven, automatic 24‐hour blood pressure recording was performed. The other nine trials (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>; <a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>) made no mention of patient posture or how blood pressure was measured. </p> <p>Three trials recorded systolic but not diastolic BP after the first intervention: (<a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>). </p> </section> <section id="CD000039-sec-0066"> <h5 class="title">Outcomes</h5> <p>The trials reported a variety of outcomes.</p> <p> <ul id="CD000039-list-0015"> <li> <p>mRS or BI or both at ≥ one month: 15 trials (<a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). Historically, trials dichotomised outcome as death or dependency, defined as mRS &gt; 2, or mRS &gt; 3, or BI &lt; 60. Ordinal analysis of ordered categorical data is statistically more efficient and provides information on severity of outcome (<a href="./references#CD000039-bbs2-0114" title="BathPMW , LeesKR , SchellingerPD , AltmanH , BlandM , et al. Statistical analysis of the primary outcome in acute stroke trials. Stroke2012;43(4):1171‐8. ">Bath 2012</a>) and recent trials have used ordinal analysis of mRS data (<a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> <li> <p>Case fatality at ≥ one month: 15 trials (<a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> <li> <p>Early neurological impairment (e.g. NIHSS, SSS) at &lt; one month: 11 trials (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>). </p> </li> <li> <p>Hospital length of stay: four trials (<a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> </ul> </p> </section> </section> <section id="CD000039-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded 66 studies because they lacked randomisation, were irrelevant to the questions addressed in the current review, or failed to provide blood pressure or outcome assessments (see <a href="./references#CD000039-sec-0142" title="">Characteristics of excluded studies</a>). </p> <section id="CD000039-sec-0068"> <h5 class="title">Other studies</h5> <p>Eight studies are either awaiting assessment (<a href="./references#CD000039-bbs2-0098" title="MAPAS trial investigators. Manipulation of Arterial Pressure in Acute ischemic Stroke. ClinicalTrials.gov2009. [NCT00848770] ">MAPAS 2009</a>; <a href="./references#CD000039-bbs2-0096" title="HosomiN , SuedaY , MasugataH , DobashiH , MuraoK , UenoM , et al. The optimal timing of antihypertensive medication administration for morning hypertension in patients with cerebral infarction. Hypertension Research2012;35(7):720‐4. ">ATTACI 2010</a>; <a href="./references#CD000039-bbs2-0099" title="Strategy for adequate blood pressure lowering in patients with intracranial atherosclerosis (STABLE‐ICAS). ClinicalTrials.gov2012. [NCT01104311] ">STABLE‐ICAS 2010</a>; <a href="./references#CD000039-bbs2-0097" title="ZanchettiA . Optimal blood pressure and cholesterol targets for preventing recurrent stroke in hypertensives ESH‐CHL‐SHOT. ClinicalTrials.gov2013. [NCT01563731] ">ESH‐CHL‐SHOT 2013</a>) or are ongoing (<a href="./references#CD000039-bbs2-0100" title="Qureshi , AI . Antihypertensive treatment of acute cerebral hemorrhage (ATACH): rationale and design. Neurocritical Care2007;6:56‐66. ">ATACH‐2 2011</a>; <a href="./references#CD000039-bbs2-0101" title="AndersonC , ENCHANTED investigators. Enhanced control of hypertension and thrombolysis stroke study: a multicentre randomised trial. Current Controlled Trials2011. [ISRCTN82387104] ">ENCHANTED 2011</a>; <a href="./references#CD000039-bbs2-0103" title="BangOY . Safety and efficacy of therapeutic induced hypertension in acute non‐cardioembolic ischemic stroke. ClinicalTrials.gov2012. [NCT01600235] ">SETIN‐HYPERTENSION 2012</a>; <a href="./references#CD000039-bbs2-0102" title="SanossianN , FAST‐BP investigators. Field Administration of Stroke Therapy‐Blood Pressure lowering (FAST‐BP). ClinicalTrials.gov2013. [NCT01811693] ">FAST‐BP 2013</a>) (<a href="#CD000039-fig-0003">Figure 3</a>). </p> </section> </section> </section> <section id="CD000039-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>Computed tomography was used prior to entry in 10 trials to identify people with ICH (<a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>) or to exclude people with ICH (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>). Another study attempted to exclude ICH through information from the history and neurological examination (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>); it may therefore have inadvertently included some participants with ICH. </p> <section id="CD000039-sec-0070"> <h4 class="title">Statistical analysis</h4> <p>Four trials compared more than one treatment against a common control group (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>). The most appropriate analysis in this situation involves dividing the control group participants equally between treatment groups to prevent control participants being counted more than once and thereby artificially narrowing the confidence intervals. </p> </section> <section id="CD000039-sec-0071"> <h4 class="title">Allocation</h4> <p>We classified allocation concealment as 'low risk', 'high risk' or 'unclear risk' according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000039-bbs2-0130" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD000039-sec-0072"> <h4 class="title">Blinding</h4> <p>The method of randomisation was given for 23 trials (<a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). Two authors were unable to describe the method of randomisation (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>) and one did not respond to our communication (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>). </p> <p>Participants and investigators were blinded to treatment as follows.</p> <p> <ul id="CD000039-list-0016"> <li> <p>Double‐blind (participant and investigator blinded): 13 trials (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>; <a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0002" title="O'BrienRE , PalmerL , JohnstonD , O'ConnellJE , HildrethAJ , GrayCS . The Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST): Candesartan gradually lowers blood pressure following acute ischaemic stroke. Proceedings of the 2nd International Conference on Hypertension, Lipids, Diabetes &amp; Stroke Prevention. 6‐8 March 2008; Prague, Czech Republic. 2008. ">ACCOST 2006</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>). </p> </li> <li> <p>Single‐blind (participant blinded): four trials (<a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> </li> <li> <p>Open‐label: six trials (<a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>; <a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>; <a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>). </p> </li> </ul> </p> </section> <section id="CD000039-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>Sixteen trials were analysed by intention‐to‐treat (ITT) (<a href="./references#CD000039-bbs2-0011" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 120 mg</a>/<a href="./references#CD000039-bbs2-0012" title="FaganSC , GengoFM , BatesV , LevineSR , KinkelWR . Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke1988;19:401‐2. ">Fagan 1988 240 mg</a>; <a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a> /<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a><a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> <p>One study excluded 10 participants from the analysis because they had been treated with antihypertensive agents for concurrent accelerated (malignant) hypertension (<a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>). </p> <p>Cardiovascular data were analysed on a per‐protocol basis and outcome data by intention‐to‐treat in one trial of lisinopril (<a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>). </p> </section> <section id="CD000039-sec-0074"> <h4 class="title">Selective reporting</h4> <p>We assessed selective reporting as low risk, high risk or unclear risk according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000039-bbs2-0130" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We did not see evidence of selective reporting in any of the trials. </p> </section> <section id="CD000039-sec-0075"> <h4 class="title">Other potential sources of bias</h4> <p>One trial randomised participants before neuroimaging and those having a non‐ischaemic stroke were subsequently withdrawn from the study (<a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>). Two trials did not state the method of analysis (<a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>). We did not find any other potential risks to the validity of the included studies. </p> </section> </section> <section id="CD000039-sec-0076"> <h3 class="title" id="CD000039-sec-0076">Effects of interventions</h3> <p>The <a href="./full#CD000039-sec-0061">Results</a> section is split into three parts. </p> <p> <ul id="CD000039-list-0017"> <li> <p>Comparisons of BP lowering with control.</p> </li> <li> <p>Comparisons of continuing versus stopping temporarily pre‐stroke antihypertensive drugs. </p> </li> <li> <p>Comparisons of BP elevation with control.</p> </li> </ul> </p> <section id="CD000039-sec-0077"> <h4 class="title">Blood pressure lowering</h4> <section id="CD000039-sec-0078"> <h5 class="title">Clinical outcomes</h5> <p>Twenty‐one trials provided data on one or more outcomes relating to treatment with:</p> <p> <ul id="CD000039-list-0018"> <li> <p>ACE‐I (lisinopril): (<a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0019" title="ShawL , PriceC , McLureS . Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): study protocol for a pilot randomised controlled trial. Trials2011;12:152. ShawL , PriceC , McLureS , HowelD , McCollE , YoungerP , et al. Paramedic Initiated Lisinopril For Acute StrokeTreatment (PIL‐FAST): results from the pilot randomised controlled trial. Emergency Medical Journal2013:1‐6. ">PIL‐FAST 2013</a>); </p> </li> <li> <p>ARA (candesartan, telmisartan): (<a href="./references#CD000039-bbs2-0001" title="KulschewskiA , LudersS , VenneklaasU , SchoderJ . Blood‐pressure rhythm in acute cerebral ischemia. Analyses from the ACCESS‐Study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Deutsche Medizinische Wochenschrift2003;128 Suppl 3:S160. [Abst.V48] MichelP , BogousslavskyJ , KernanWN , SchraderJ , LudersS , KulschewskiA , et al. ACCESS Study: blood pressure effect?. Stroke2003;34(12):e237‐8. SchraderJ , LudersS , KulschewskiA , BergerJ , ZidekW , TreibJ , et al. The ACCESS study: evaluation of acute candesarten cilexetil therapy in stroke survivors. Stroke2003;34:1699‐703. ">ACCESS 2003</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>; <a href="./references#CD000039-bbs2-0028" title="YuK‐H , OhM‐S , HongK‐S , KangD‐W , ParkJ‐M , BaeH‐J , et al. Safety and efficacy of modest blood pressure reduction with valsartan in acute ischemic stroke. International Stroke Conference. Stroke, 2013:44: AWP63. ">VENTURE 2013</a>); </p> </li> <li> <p>ß‐RA (labetalol): (<a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>); </p> </li> <li> <p>CCB (nimodipine): (<a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>); </p> </li> <li> <p>NO donor (glyceryl trinitrate): (<a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>); </p> </li> <li> <p>intensive blood pressure lowering: (<a href="./references#CD000039-bbs2-0016" title="AndersonC . INTERACT: Intensive blood pressure reduction in acute cerebral haemorrhage trial. http://www.thegeorgeinstitute.org/research/neurological‐diseases2005. AndersonCS , ButcherK , HuangY , MorgensternL . INTERACT (Intensive blood pressure reduction in acute cerebral haemorrhage trial): rationale, design, and early results. Journal of the Neurological Sciences2005;238 Suppl 1:S381. AndersonCS , HuangY , WangJ , MorgensternL , ButcherK , NealB , et al. INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial) rationale and design. Proceedings of the International Stroke Conference. 2006. AndersonCS , HuangY , WangJG , ArimaH , NealB , PengB , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology2008;7(5):391‐9. ">INTERACT pilot 2008</a>; <a href="./references#CD000039-bbs2-0017" title="KochS , RomanoJG , FortezaAM , OteroCM , RabinsteinAA . Rapid blood pressure reduction in acute intracerebral hemorrhage: feasibility and safety. Neurocritical Care2008;8:316‐21. ">Koch 2008</a>; <a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0004" title="HeJ , ZhangY , XuT , ZhaoQ , WangD , ChenCS , et al. CATIS Investigators. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA2014;311(5):479‐89. ">CATIS 2013</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>); </p> </li> <li> <p>blood pressure elevation (phenylephrine): (<a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>). </p> </li> </ul> </p> <section id="CD000039-sec-0079"> <h6 class="title">Death or dependency, end of trial</h6> <section id="CD000039-sec-0080"> <p><b>Drug class</b></p> <p>Combined death or dependency was assessed using the mRS at the end of follow‐up. Data were available for 15,489 participants recruited into 14 trials (<a href="./references#CD000039-fig-0004" title="">Analysis 1.1</a>). We observed no significant difference between blood pressure lowering and control (OR 0.98; 95% CI 0.92 to 1.05), and heterogeneity was minimal. No individual comparison within drug classes or BP lowering strategies was significant (<a href="./references#CD000039-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD000039-sec-0081"> <p><b>Stroke type</b></p> <p>The effect of lowering blood pressure did not vary by stroke subtype (ischaemic stroke, mixed stroke, ICH) across 14 trials (<a href="./references#CD000039-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD000039-sec-0082"> <p><b>Stroke location</b></p> <p>The effect of lowering blood pressure did not vary by stroke location (ICH deep or not, ischaemic stroke cortical or subcortical) across six trials with 11951 participants (<a href="./references#CD000039-fig-0005" title="">Analysis 1.2</a>). Although there was insufficient evidence to assess heterogeneity, blood pressure lowering in deep ICH almost reached significance (OR 0.86; 95% CI 0.73 to 1.00, P value = 0.06) (<a href="./references#CD000039-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD000039-sec-0083"> <p><b>Time to treatment</b></p> <p>Data from 15 trials involving 15,520 participants were available. There was significant reduction in death or dependency if treatment was administered during the hyperacute period and in hospital (OR 0.87; 95% CI 0.76 to 0.99, P value = 0.03). Recruitment of participants later than this was associated with no benefit (<a href="./references#CD000039-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD000039-sec-0084"> <h6 class="title">Death, early and end of trial</h6> <p>There was no overall effect of treatment on early death or death at end of trial (<a href="./references#CD000039-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD000039-fig-0011" title="">Analysis 1.8</a>). When considering subgroups, no differences existed when analysed by drug class (<a href="./references#CD000039-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD000039-fig-0011" title="">Analysis 1.8</a>), stroke type (<a href="./references#CD000039-fig-0009" title="">Analysis 1.6</a>; <a href="./references#CD000039-fig-0012" title="">Analysis 1.9</a>), or time to treatment (<a href="./references#CD000039-fig-0010" title="">Analysis 1.7</a>; <a href="./references#CD000039-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD000039-sec-0085"> <h6 class="title">Barthel Index (disability), end of trial</h6> <p>We assessed the BI at the end of follow‐up in two trials with 4350 participants (<a href="./references#CD000039-fig-0014" title="">Analysis 1.11</a>). Although we observed no significant difference between blood pressure lowering and control (OR 0.63; 95% CI ‐3.28 to ‐4.54) (<a href="./references#CD000039-fig-0014" title="">Analysis 1.11</a>) and did not vary with stroke type (<a href="./references#CD000039-fig-0015" title="">Analysis 1.12</a>), BI scores were lower if treatment was started within six hours of stroke onset (<a href="./references#CD000039-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD000039-sec-0086"> <h6 class="title">Neurological deterioration, early</h6> <p>There was no overall difference in the rate of early neurological deterioration across seven trials (<a href="./references#CD000039-fig-0017" title="">Analysis 1.14</a>). Subgroup differences were not present when analysed by drug class or intensity (<a href="./references#CD000039-fig-0017" title="">Analysis 1.14</a>), or stroke type (<a href="./references#CD000039-fig-0018" title="">Analysis 1.15</a>). However, subgroup differences were apparent when assessed by time to treatment (<a href="./references#CD000039-fig-0019" title="">Analysis 1.16</a>); specifically, an increase in neurological deterioration was seen in participants with acute stroke (≤ 48 hours post stroke) (OR 1.39; 95% CI 1.07 to 1.81, P value = 0.01) but not when trials specifically treated earlier during the ultra‐acute and hyper‐acute periods. </p> </section> <section id="CD000039-sec-0087"> <h6 class="title">Quality of life</h6> <p>Quality of life, assessed using the EQ‐5D and transformed into a Health Utility Status, was assessed in three trials (<a href="./references#CD000039-fig-0020" title="">Analysis 1.17</a>; <a href="./references#CD000039-fig-0021" title="">Analysis 1.18</a>). Health Utility scores were higher/better with blood pressure lowering (MD 0.02; 95% CI 0.01 to 0.04). However, heterogeneity was apparent between studies (I<sup>2</sup> = 76.0%) with a significant result in <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>, but not <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>. When broken down into stroke types, participants with ICH in <a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a> treated with blood pressure lowering tended to report a better quality of life (<a href="./references#CD000039-fig-0021" title="">Analysis 1.18</a>). When assessed by time to treatment, Health Utility Status scores were higher in participants treated ≤ six hours (MD 0.06; 95% CI 0.03 to 0.08), but not when treated later (<a href="./references#CD000039-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD000039-sec-0088"> <h6 class="title">Length of stay</h6> <p>Length of stay was not influenced by lowering blood pressure and there were no subgroup differences by type of intervention, stroke type or time to treatment (<a href="./references#CD000039-fig-0023" title="">Analysis 1.20</a>; <a href="./references#CD000039-fig-0024" title="">Analysis 1.21</a>; <a href="./references#CD000039-fig-0025" title="">Analysis 1.22</a>). </p> </section> </section> <section id="CD000039-sec-0089"> <h5 class="title">Haemodynamic measures</h5> <section id="CD000039-sec-0090"> <h6 class="title">Blood pressure</h6> <p>The effect of different blood pressure‐lowering strategies on blood pressure after the first dose are summarised in <a href="./references#CD000039-fig-0026" title="">Analysis 1.23</a> and <a href="./references#CD000039-fig-0032" title="">Analysis 1.29</a>, and in <a href="#CD000039-tbl-0001">Table 1</a>. Altogether, 24 trials studied 15,432 participants; most participants received an ARA, a NO donor or intensive blood pressure lowering. The focus for the following comments are on systolic rather than diastolic blood pressure. The magnitude of blood pressure reduction varied between ‐4.6/‐2.5 mmHg for oral ARA (primarily candesartan and telmisartan) and ‐13.7/‐7.9 mmHg for ACE‐Is. When assessed by stroke type, heterogeneity was present; slightly larger reductions in blood pressure were seen in participants with ICH (‐11.8/‐5.1 mmHg) with mixed stroke intermediate (‐7.9/‐3.0 mmHg) and ischaemic stroke least (‐7.0/‐3.1 mmHg) (<a href="./references#CD000039-fig-0025" title="">Analysis 1.22</a>; <a href="./references#CD000039-fig-0033" title="">Analysis 1.30</a>). Similarly, the magnitude of reduction varied by time to randomisation or treatment (I<sup>2</sup> = 89%); a graded decrease was seen by time with the largest reduction occurring in participants treated during the ultra‐acute/pre‐hospital (‐16.0/‐15.0 mmHg), hyper‐acute/hospital (‐13.4/‐7.5 mmHg), acute (‐8.2/‐2.8 mmHg) and sub‐acute (‐7.3/‐4.9 mmHg) periods. </p> <div class="table" id="CD000039-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Blood pressure changes after first dose</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trials</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% CI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2 %</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DBP</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% CI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACE‐I, oral</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.0 to ‐7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.7 to 1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACE‐I, sublingual</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐17.6 to 5.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+2.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.5 to 9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3408</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐8 to ‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.3 to ‐0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>α‐2 adrenoceptor agonist</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐41.5 to 14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐15.4 to 11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ß‐receptor antagonist, oral</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.3 to ‐2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13 to 2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ß‐receptor antagonist, iv</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐27.4 to ‐5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐17.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐25.3 to ‐9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, oral</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐17.2 to 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.3 to 2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, iv</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐24.4 to 4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐12.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐31.4 to 5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitric oxide donor</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4192</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐14.5 to ‐4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.4 to ‐2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diuretic, thiazide‐like</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐38.6 to ‐1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low BP target</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7421</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐15.3 to ‐7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐15.7 to 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15432</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13.7, ‐8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.4 to ‐2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACE‐I: angiotensin converting enzyme inhibitors<br/> ARA: angiotensin receptor antagonist<br/> BP: blood pressure<br/> DBP: diastolic blood pressure<br/> SBP: systolic blood pressure<br/> iv: intravenous </p> </div> </div> <p>The effect of the various types of intervention over the first week are summarised in <a href="#CD000039-tbl-0002">Table 2</a>. </p> <div class="table" id="CD000039-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood pressure changes by type of intervention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACE‐I, oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐21.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACE‐I, sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Angiotensin receptor antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alpha‐2 adrenoceptor agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐21.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta‐receptor antagonist, oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta‐receptor antagonist, iv</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐31.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diuretic, thiazide‐like</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACE‐I: angiotensin converting enzyme inhibitors<br/> BP: blood pressure<br/> SBP: systolic blood pressure<br/> iv: intravenous </p> </div> </div> </section> <section id="CD000039-sec-0091"> <h6 class="title">Heart rate</h6> <p>Thirteen trials reported heart rate measurements (<a href="./references#CD000039-bbs2-0018" title="LiskDR , GrottaJC , LamkiLM , TranHD , TaylorJW , MolonyDA , et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Archives of Neurology1993;50:855‐62. ">Lisk 1993</a>; <a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>; <a href="./references#CD000039-bbs2-0007" title="DykerAG , GrossetDG , LeesK . Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke1997;28:580‐3. DykerAG , GrossetDG , LeesKR . Effect of perindopril on blood pressure and cerebral blood flow after acute ischaemic stroke. European Journal of Neurology1995;2 Suppl 2:7. ">Dyker 1997</a>; <a href="./references#CD000039-bbs2-0003" title="BathPMW , PathansaliR , BathFJ . Effect of nitric oxide on blood pressure in acute stroke. The Challenge of Stroke. Lancet Conference, Montreal. 1998:40‐1. BathPMW , PathansaliR , IddendenR , BathFJ . The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke. Cerebrovascular Diseases1999;9 Suppl 1:101. Bath , PMW , PathansaliR , IddendenR , BathFJ . The effect of transdermal glyceryl trinitrate, a nitric oxide donor on blood pressure and platelet function in acute stroke. Cerebrovascular Diseases2000;11:265‐72. ">Bath 2000</a>; <a href="./references#CD000039-bbs2-0023" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5 mg</a>/<a href="./references#CD000039-bbs2-0022" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 5/10 mg</a>/<a href="./references#CD000039-bbs2-0021" title="RashidP , WeaverC , Leonardi‐BeeJ , BathF , FletcherS , BathP . The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac haemodynamics, and plasma nitric oxide levels in acute stroke. Journal of Stroke and Cerebrovascular Diseases2003;12(3):143‐51. ">Rashid 2003 10 mg</a>; <a href="./references#CD000039-bbs2-0008" title="EamesPJ , RobinsonTG , PaneraiRB , PotterJF . Bendrofluazide fails to reduce elevated blood pressure levels in the immediate post‐stroke period. Cerebrovascular Diseases2005;19:253‐9. ">Eames 2005</a>; <a href="./references#CD000039-bbs2-0029" title="WillmotM , GhadamiA , ClarkeW , WeaverC , WardlawJ , BathP . Effect of glyceryl tri‐nitrate, a nitric oxide donor, on blood pressure and cerebral blood flow in acute/subacute stroke. Journal of the Neurological Sciences2005;238 Suppl 1:Abst OPL104. WillmotM , GhadamiA , WhysallB , ClarkeW , WardlawJ , BathPMW . Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension2006;47:1209‐15. WillmotM , GhadamiA , WhysallB , WeaverC , BathP . Glyceryl trinitrate, a nitric oxide donor, lowers blood pressure but not cerebral blood flow in patients with acute/subacute stroke. Cerebrovascular Diseases2005;19 Suppl 2:31. ">Willmot 2006</a>; <a href="./references#CD000039-bbs2-0010" title="EvesonDJ , RobinsonTG , PotterJF . Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow up. American Journal of Hypertension2007;20:270‐7. ">Eveson 2007</a>; <a href="./references#CD000039-bbs2-0020" title="BathPMW , MartinRH , PaleschY , CottonD , YusufS , SaccoR , PRoFESS Study Group. Effects of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke2009;40:3541‐6. SaccoRL , DienerHC , YusufS , CottonD , ÔunpuuS , LawtonWA , the PRoFESS Study Group. Aspirin and extended‐release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine2008;359:1238‐51. ">PRoFESS 2009</a>; <a href="./references#CD000039-bbs2-0014" title="ButcherK , JeerakathilT , EmeryD , DowlatshahiD , HillMD , SharmaM , et al. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: Intracerebral haemorrhage ADAPT. International Journal of Stroke2010;5:227‐33. ButcherKS , JeerakathilT , HillM , DemchukAM , DowlatshahiD , CouttsSB , Intracerebral haemorrhage ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke2013;44:620‐6. ">ICH‐ADAPT 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0026" title="SareGM , GhadamiA , AnkolekarS , EnglandT , HammondsF , AdrianM , et al. Effect of telmisartan on cerebral and systemic haemodynamics in patients with recent ischaemic stroke: a randomised controlled trial. ISRN Stroke2013;2013:1‐9. ">TAST 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). The heart rate for glyceryl trinitrate increased at day one (MD 4.5 bpm; 95% CI 2 to 8) (<a href="./references#CD000039-fig-0040" title="">Analysis 1.37</a>) (<a href="#CD000039-tbl-0003">Table 3</a>). Intravenous CCBs reduced heart rate at day one (<a href="./references#CD000039-bbs2-0027" title="UzunerN , GucuyenerD , OzdemirG . The interaction between nimodipine and systemic blood pressure and pulse rate. Unpublished manuscript. UzunerN , OzdemirG , GucuyenerD . The interaction between nimodipine and systemic blood pressure and pulse rate. Pan‐European consensus meeting on stroke management. 8‐10 November 1995, Helsingborg, Sweden. 1995. ">Uzuner 1995</a>) (<a href="./references#CD000039-fig-0040" title="">Analysis 1.37</a>). </p> <div class="table" id="CD000039-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Heart rate changes at day 1</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% CI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACE (oral)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐40.4 to 40.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alpha‐2 adrenoceptor agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.7 to 2.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐27.4 to ‐6.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 to 7.6</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACE: angiotensin converting enzyme <br/> iv: intravenous </p> </div> </div> </section> </section> </section> <section id="CD000039-sec-0092"> <h4 class="title">Continuing versus stopping pre‐stroke antihypertensive drugs</h4> <p>Two trials tested whether pre‐stroke antihypertensives should be continued in the immediate post‐stroke period, or stopped temporarily (<a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). The total number of participants numbered 2860. </p> <section id="CD000039-sec-0093"> <h5 class="title">Clinical outcomes</h5> <section id="CD000039-sec-0094"> <h6 class="title">Death or dependency, end of trial</h6> <p>There was no significant difference in mRS at day 90 between those participants assigned to continue or stop antihypertensives (OR 1.06; 95% CI 0.91 to 1.24) (<a href="./references#CD000039-fig-0043" title="">Analysis 2.1</a>). Within subgroups, the effect of continuing versus stopping antihypertensives did not differ by stroke types or time to treatment across both trials (<a href="./references#CD000039-fig-0044" title="">Analysis 2.2</a> and <a href="./references#CD000039-fig-0045" title="">Analysis 2.3</a>). </p> </section> <section id="CD000039-sec-0095"> <h6 class="title">Death, early and at the end of trial</h6> <p>The rates of death at the end of treatment, and at the end of trial, did not differ between the treatment groups (<a href="./references#CD000039-fig-0046" title="">Analysis 2.4</a> and <a href="./references#CD000039-fig-0049" title="">Analysis 2.7</a>). No significant differences were observed by stroke types or time to treatment (<a href="./references#CD000039-fig-0047" title="">Analysis 2.5</a>; <a href="./references#CD000039-fig-0048" title="">Analysis 2.6</a>; <a href="./references#CD000039-fig-0050" title="">Analysis 2.8</a>; <a href="./references#CD000039-fig-0051" title="">Analysis 2.9</a>). </p> </section> <section id="CD000039-sec-0096"> <h6 class="title">Barthel Index</h6> <p>Barthel Index scores were lower in participants assigned to continue treatment (MD ‐3.18; 95% CI ‐0.55 to ‐5.80, P value = 0.02) (<a href="./references#CD000039-fig-0052" title="">Analysis 2.10</a>). </p> <p><b>Neurological deterioration, early</b> </p> <p>The rate of death at the end of treatment did not differ between the treatment groups (<a href="./references#CD000039-fig-0053" title="">Analysis 2.11</a>). </p> </section> <section id="CD000039-sec-0097"> <h6 class="title">Quality of life</h6> <p>Quality of life, assessed using the EQ‐5D and transformed into a Health Utility Status, was lower (i.e. worse) in participants randomised to continue pre‐stroke antihypertensive drugs (MD ‐0.03; 95% CI ‐0.05 to ‐0.01, P value = 0.008) (<a href="./references#CD000039-fig-0054" title="">Analysis 2.12</a>). </p> </section> </section> <section id="CD000039-sec-0098"> <h5 class="title">Haemodynamic measures</h5> <section id="CD000039-sec-0099"> <h6 class="title">Blood pressure</h6> <p>Blood pressure was lower by ‐7.9/‐1.2 mmHg at the first measurement after randomisation in participants randomised to continue treatment with the reduction in systolic BP much greater in <a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a> than in <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a> (<a href="./references#CD000039-fig-0056" title="">Analysis 2.14</a>). By the end of treatment, blood pressure was lower by ‐11.3/‐6.4 mmHg in the continue group. </p> </section> <section id="CD000039-sec-0100"> <h6 class="title">Heart rate</h6> <p>Data were only available for <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>. Heart rate was significantly lower by 3.2 bpm by end of treatment in those who were randomised to continue treatment (<a href="./references#CD000039-fig-0063" title="">Analysis 2.21</a>). </p> </section> </section> </section> <section id="CD000039-sec-0101"> <h4 class="title">Blood pressure elevation therapy in acute stroke</h4> <section id="CD000039-sec-0102"> <h5 class="title">Phenylephrine</h5> <p>Phenylephrine non‐significantly increased systolic blood pressure at 24 hours (MD 21 mmHg; 95% CI ‐13 to 55 mmHg), but had no significant effect on diastolic blood pressure (<a href="./references#CD000039-bbs2-0013" title="HillisAE , UlatowskiJA , BarkerPB , TorbeyM , ZiaiW , BeauchampNJ , et al. A pilot randomised trial of induced blood pressure elevation: effects on function and focal perfusion in acute and subacute stroke. Cerebrovascular Diseases2003;16:236‐48. ">Hillis 2003</a>) (<a href="./references#CD000039-fig-0067" title="">Analysis 3.4</a>). Insufficient data were available on clinical outcomes. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000039-sec-0103" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000039-sec-0103"></div> <p>Twenty‐six trials, involving 17,011 participants with stroke, assessed the effects of deliberate blood pressure alteration. </p> <section id="CD000039-sec-0104"> <h3 class="title" id="CD000039-sec-0104">Blood pressure lowering</h3> <p>The results come from 24 trials that studied 15,432 participants.</p> <section id="CD000039-sec-0105"> <h4 class="title">Clinical outcomes</h4> <p>Overall, lowering blood pressure did not improve outcome, whether assessed as death, combined death or dependency, neurological deterioration or quality of life. These findings were maintained irrespective of type of intervention (drug class, intensity of lowering) or type of stroke. However, when assessed by time to treatment, very early blood pressure lowering (before hospital presentation or within six hours of stroke onset) was associated with reduced death or dependency, and improved quality of life (<a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>). </p> </section> <section id="CD000039-sec-0106"> <h4 class="title">Haemodynamic effects</h4> <p>All the studied antihypertensive drug classes lowered blood pressure during the period of treatment. Reductions in blood pressure after the first treatment varied between ‐4.6/‐2.5 mmHg for oral ARA and ‐21.0/‐7.9 mmHg for ACE‐I. Slightly larger reductions in blood pressure were seen in participants with ICH (‐11.8/‐5.1 mmHg) than in those with ischaemic stroke (‐7.0/‐3.1 mmHg). The largest reductions were seen if treatment was started very early before hospital presentation (‐16.0/‐15.0 mmHg); smaller reductions occurred if treatment was started beyond 48 hours after stroke onset (‐7.3/‐4.9 mmHg). </p> </section> <section id="CD000039-sec-0107"> <h4 class="title">Discussion</h4> <p>A variety of hypotheses can be postulated for why functional outcome was better if blood pressure lowering was started very early after stroke. First, the magnitude of blood pressure lowering may be important since the greatest improvement in outcome occurred when treatment was started early. Second, the type of intervention may be important since improved outcome was seen with early intensive blood pressure lowering (<a href="./references#CD000039-bbs2-0015" title="AndersonC . INTERACT2 the second intensive blood pressure reduction in acute cerebral haemorrhage trial. ClinicalTrials.gov2008. [NCT00716079] AndersonCS , HeeleyE , HuangY , WangJ , StapfC , DelcourtC , INTERACT2 Investigators. Rapid blood‐pressure lowering in patients with acute intracerebral haemorrhage. New England Journal of Medicine2013;368(25):2355‐65. DelcourtC , HuangY , WangJ , HeeleyE , LindleyR , StapfC , et al. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). International Journal of Stroke2010;5:110‐6. ">INTERACT‐2 2013</a>), and early nitrate administration (<a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). Conversely, apparent hazard was seen with ARA drugs (<a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>; <a href="./references#CD000039-bbs2-0133" title="JusufovicM , SandsetEC , BathPMW , BergeE . Blood pressure lowering treatment with candesartan in patients with acute hemorrhagic stroke. In press. ">Jusufovic 2014</a>). </p> <p>Perhaps surprisingly, stroke type may not be particularly relevant since differential effects on outcome were not seen for ischaemic stroke versus ICH. </p> <p>In summary, very early treatment with an appropriate agent or target blood pressure may be the most important strategy to test in the future, irrespective of stroke type. Importantly, systolic blood pressure should not be lowered excessively (&gt; 20%), at least in ischaemic stroke, since trials of intravenous CCBs found that these worsened outcome (<a href="./references#CD000039-bbs2-0038" title="BridgersSL , KochG , MuneraC , KarwonM , KurtzNM . Intravenous nimodipine in acute stroke: interim analysis of randomized trials. Stroke1991;22:153. ">Bridgers 1991</a>; <a href="./references#CD000039-bbs2-0154" title="WahlgrenNG , MacMahonDG , DeKeyserJ , IndredavikB , RymanT , for the INWEST Study Group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovascular Diseases1994;4:204‐10. ">Wahlgren 1994</a>). </p> </section> </section> <section id="CD000039-sec-0108"> <h3 class="title" id="CD000039-sec-0108">Continue versus stop pre‐stroke antihypertensive drugs</h3> <p>The results come from two trials that studied 2860 participants (<a href="./references#CD000039-bbs2-0006" title="Cossacs Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensive Collaborative Study): rationale and design. Journal of Hypertension2005;23(2):455‐8. RobinsonTG , PotterJF , FordGA , BulpittCJ , ChernovaJ , JaggerC , COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post‐Stroke AntihypertensivesCollaborative Study (COSSACS): a prospective, randomised,open, blinded‐endpoint trial. Lancet Neurology2010;9(8):767‐75. ">COSSACS 2010</a>; <a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> <section id="CD000039-sec-0109"> <h4 class="title">Clinical outcomes</h4> <p>The findings were mixed with some comparisons, in particular dependency (mRS), death, and neurological deterioration, neutral for the comparison of continue versus stop pre‐stroke antihypertensive drugs. In contrast, measures of disability (BI) and quality of life (EQ‐5D, transformed into a Health Utility Status) were worse in participants randomised to continue treatment immediately. </p> </section> <section id="CD000039-sec-0110"> <h4 class="title">Haemodynamic effects</h4> <p>Immediately continuing antihypertensive drugs taken before stroke was associated with a lower blood pressure by ‐7.9/‐1.2 mmHg at the first measurement after randomisation, and ‐11.3/‐6.4 mmHg by end‐of‐treatment. </p> </section> <section id="CD000039-sec-0111"> <h4 class="title">Discussion</h4> <p>The discrepancy in findings for two measures of functional outcome, mRS and BI, is challenging to explain. First, it may represent chance such that no difference exists between the interventions. Second, it could reflect outcome bias since it is not possible to test this question in a double‐blind placebo‐controlled design. Nevertheless, both trials used blinded outcome assessment for both mRS and BI. Further, since a majority of stroke physicians tend to continue treatment in routine practice (<a href="./references#CD000039-bbs2-0109" title="BathPMW , WeaverC , IddendenR , BathFJ . A trial of blood pressure reduction in acute stroke. Age and Ageing2000; Vol. 29:551‐5. ">Bath 2000b</a>), the result seen across the two results is counter‐intuitive. Last, the difference may be real in which case mRS, usually considered to be the optimal functional outcome in stroke trials (<a href="./references#CD000039-bbs2-0135" title="LeesKR , BathPM , SchellingerPD , KerrDM , FultonR , HackeW , et al. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke2012;43(4):1163‐70. ">Lees 2012</a>), failed to detect a difference in contrast to a comparison of BI scores. </p> <p>If continuing drugs immediately is, indeed, hazardous, then the two trials do not identify the cause. Drugs that attenuate stress hormones, in particular that down‐regulate the renin‐angiotensin‐aldosterone‐system (RAAS) were commonly taken before stroke, e.g. ACE‐I, ARA and ß‐receptor antagonists. Initiating these drugs in the acute phase of stroke has been associated with harm (<a href="./references#CD000039-bbs2-0034" title='BarerDH , CruickshankJM , EbrahimSB , MitchellJRA . Low dose blockade in acute stroke ("BEST" trial): an evaluation. British Medical Journal1988;296:737‐41. '>BEST 1988</a>; <a href="./references#CD000039-bbs2-0025" title="SandsetEC , BathPMW , BoysenG , JatuzisD , KõrvJ , LüdersS , SCAST Study Group. The angiotensin‐receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo‐controlled, double‐blind trial. Lancet2011;377:741‐50. SandsetEC , MurrayG , BoysenG . Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised and placebo‐controlled clinical trial. International Journal of Stroke2010;5:423‐7. [NCT00120003] ">SCAST 2011</a>), so it can be postulated that continuing these during the acute phase of stroke is potentially harmful. Alternatively, continuing drugs in people who are dysphagic and who do not have safe enteral access for feeding may be hazardous through aspiration of these drugs and then the development of pneumonia. The ENOS trial gives some support for this hypothesis (<a href="./references#CD000039-bbs2-0009" title="BathPMW , WoodhouseL , ScuttP , KrishnanK , WardlawJM , BerezckiD , et al. Glyceryl trinitrate vs. control, and continue versus stop temporarily prior antihypertensive therapy in acute stroke: main results from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. Lancet (in press)2014. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). International Journal of Stroke2006;1:2459. ">ENOS 2014</a>). </p> <p>The main implication for clinicians is that it is reasonable to withhold BP‐lowering drugs until patients are medically and neurologically stable, and have suitable oral or enteral access, after which drugs can then be reintroduced. </p> </section> </section> <section id="CD000039-sec-0112"> <h3 class="title" id="CD000039-sec-0112">General</h3> <p>An important problem with some of the trials was the absence of detailed information on how blood pressure was measured. Hence, the quality of blood pressure readings is unknown. It is essential that future trials describe in detail how blood pressure is measured by including the following information. </p> <p> <ol id="CD000039-list-0019"> <li> <p>Equipment: manufacturer, model, measurement method (mercury, anaeroid or oscillometry, and manual or automatic), and whether the equipment has been independently validated, and if so by whom. </p> </li> <li> <p>Measurer: who measured blood pressure, and how they were trained, assessed, re‐trained and re‐assessed. </p> </li> <li> <p>Measurements: the number of readings at each time point, site of measurement (brachial, finger, etc) and what position the person was in (supine, sitting, standing). </p> </li> </ol> </p> <p>Little is known about the effect of blood pressure altering in older people with acute stroke, who comprise the largest group of patients, including those with ischaemic stroke who need thrombolysis. Of the trials, only two had mean age over 75 years contributing to a total of 98 participants (<a href="./references#CD000039-bbs2-0005" title="PotterJ , MistriA , BrodieF , ChernovaJ , WilsonE , JaggerC , et al. Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) – a randomised controlled trial. Health Technology Assessment2009;13(9: iii, ix‐xi):1‐73. PotterJF , RobinsonTG , FordGA , MistriA , JamesM , ChernovaJ , et al. Controlling hypertension and hypotension immediately post‐stroke (CHHIPS): a randomised, placebo‐controlled, double‐blind pilot trial. Lancet Neurology2009;8(1):48‐56. The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) pilot trial: rationale and design. Journal of Hypertension2005;23:649‐55. ">CHHIPS 2009</a>; <a href="./references#CD000039-bbs2-0024" title='AnkolekarS , FullerM , CrossI , RentonC , CoxP , SpriggN , et al. Feasibility of an Aabulance‐based stroke trial, and safety of glyceryl trinitrate in ultra‐acute stroke: the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT). Stroke2013;44(11):3120‐8. [ISRCTN66434824] AnkolekarS , GareS , GeeganageC , FullerM , StokesL , SpriggN , et al. Determining the feasibility of ambulance‐based randomised controlled trials in patients with ultra‐acute stroke: study protocol for the "Rapid Intervention with GTN in Hypertensive stroke Trial" (RIGHT). Stroke Research and Treatment2012;2012:385753. [ISRCTN66434824] '>RIGHT 2013</a>). The number and proportion of older people is likely to increase with population ageing. As the variation in response by individuals to blood pressure modulating agents increases with age, e.g. related to concurrent isolated systolic hypertension or cardiac dysfunction, it may be inappropriate to assume that the effects of changing blood pressure seen in younger populations will necessarily be the same in older ones. </p> <p>This review is Part 1 of the Blood pressure in Acute Stroke Collaboration and reports only those trials that specifically set out to alter blood pressure in people with acute stroke. Part 2 of the project assesses all RCTs in acute stroke where vasoactive drugs were administered and includes all those studies covered in Part 1. Although progress has been made in the number and quality of stroke trials in the last few years, a substantial number of questions remain. The number of participants included in this review is very small in comparison to the global burden of stroke (about 15,000,000 per year worldwide). At present, any benefit of treatment is small, and additional data are required to recommend changes to routine clinical practice. The centres that took part in the trials were interested and familiar with the management of acute stroke. To extrapolate these results in routine clinical practice to less specialist centres could result in greater hazard or completely negate any potential benefit. Therefore, there is a need for new centres to participate in trials. Further evidence is needed on: </p> <p> <ul id="CD000039-list-0020"> <li> <p>how to select participants;</p> </li> <li> <p>the influence of age, time of onset, stroke subtype, severity, choice of drug, dose, route of administration and blood pressure variability, on response to active changes in blood pressure. </p> </li> </ul> </p> <p>Recent guidelines based on the non‐systematic analysis of (largely) observational data recommend that hypertension should not be treated for up to two weeks after an ischaemic stroke unless severe hypertension, hypertensive encephalopathy, heart failure, cardiac ischaemia, aortic dissection, or continued intracerebral bleeding are present (<a href="./references#CD000039-bbs2-0140" title="O'ConnellJE , GrayCS . Treating hypertension after stroke. BMJ1994;308:1523‐4. ">O'Connell 1994</a>; <a href="./references#CD000039-bbs2-0124" title="ToniD , ChamorroA , KasteM , LeesK , WahlgrenNG , HackeW . Acute treatment of ischaemic stroke. Cerebrovascular Diseases2004;17 Suppl 2:30‐46. ">EUSI 2004</a>; <a href="./references#CD000039-bbs2-0105" title="MorgensternLB , Hemphill IIIJC , AndersonC , BeckerC , BroderickJP , ConnollyES , et al. Guidelines for the management of spontaneous intracerebral haemorrhage. Stroke2010;41:2108‐29. ">AHA‐HS 2010</a>; <a href="./references#CD000039-bbs2-0106" title="JauchEC , SaverJL , Adams JrHP , BrunoA , ConnorsB , DemaerschalkBM , et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke2013;44:870‐947. ">AHA‐IS 2013</a>). Persistent hypertension after two weeks should be treated since the risk of stroke in people with cerebrovascular disease is dependent on systolic and diastolic blood pressure (<a href="./references#CD000039-bbs2-0147" title="RodgersA , MacMahonS , GambleG , SlatteryJ , SandercockP , WarlowC , for the United Kingdom Transient Ischaemic stroke Attack Collaborative Group. Blood pressure and risk of stroke in patients with cerebrovascular disease. BMJ1996;313:147. ">Rodgers 1996</a>). In <a href="./references#CD000039-bbs2-0143" title="PROGRESS Collaborative group. Randomised trial of a perindopril‐based blood pressure‐lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033‐41. ">PROGRESS 2001</a>, perindopril (with or without indapamide) reduced the risk of stroke among both hypertensive and non‐hypertensive participants with a history of stroke or transient ischaemic attack. Further, evidence from the Heart Outcomes Prevention Evaluation (HOPE) trial suggests that an ACE‐I may reduce stroke and other vascular events in people with prior cerebrovascular disease (<a href="./references#CD000039-bbs2-0131" title="The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. New England Journal of Medicine2000;342:145‐53. ">HOPE 2000</a>). Overall, lowering blood pressure in people with chronic stroke reduces the subsequent risk of recurrence (<a href="./references#CD000039-bbs2-0144" title="RashidP , Leonardi‐BeeJ , BathP . Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke2003;34:2741‐8. ">Rashid 2003</a>). </p> </section> <section id="CD000039-sec-0113"> <h3 class="title" id="CD000039-sec-0113">Summary of main results</h3> <p>In this updated review, blood pressure lowering did not improve functional outcome. However, early initiation of treatment might be beneficial, and further studies are required to test this specific question. Immediately continuing pre‐stroke antihypertensive drugs appears to be associated with a worse functional outcome and lower quality of life; hence, it is reasonable to delay treatment until patients are stable and have oral or enteral access to allow safe administration of drugs. </p> </section> <section id="CD000039-sec-0114"> <h3 class="title" id="CD000039-sec-0114">Overall completeness and applicability of evidence</h3> <p>The included trials are an excellent start to answering the question of optimal blood pressure management in acute stroke. The lack of a definitive result based on data from more than 16,000 participants confirms that the question is complex and future trials need to refine trial design, especially focusing on very early treatment. </p> </section> <section id="CD000039-sec-0115"> <h3 class="title" id="CD000039-sec-0115">Quality of the evidence</h3> <p>The quality of the included studies was variable. Methods of randomisation and allocation concealment were not always clear. Not all trials contributed to each outcome. Details of blood pressure recording including equipment, number of readings and patient positioning were not provided in some studies. Trials in the last decade were more standardised compared with earlier ones when reporting baseline stroke characteristics, primary and secondary outcomes. Outcome assessment was blinded in recent large RCTs and clearly reported in trial protocols. Trials were largely not representative of unselected stroke populations around the world ‐ participants tended to be younger, have fewer comorbidities and be conscious, so that poor outcomes were less common than might be expected. </p> </section> <section id="CD000039-sec-0116"> <h3 class="title" id="CD000039-sec-0116">Potential biases in the review process</h3> <p>This review follows an extensive literature search by both the Cochrane Stroke Review Group, and the authors, and without any language restrictions. Hence the risk of study inclusion bias is low. </p> </section> <section id="CD000039-sec-0117"> <h3 class="title" id="CD000039-sec-0117">Agreements and disagreements with other studies or reviews</h3> <p>The limited data mean that we can draw no firm conclusions, as shown in other reviews.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000039-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Blood pressure lowering therapy in acute stroke, outcome: 1.1 Death or dependency, end of trial by intervention." data-id="CD000039-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Blood pressure lowering therapy in acute stroke, outcome: 1.1 Death or dependency, end of trial by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Blood pressure lowering therapy in acute stroke, outcome: 1.23 SBP, first after randomisation, by intervention." data-id="CD000039-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Blood pressure lowering therapy in acute stroke, outcome: 1.23 SBP, first after randomisation, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Results of database search" data-id="CD000039-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Results of database search</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 1 Death or dependency, end of trial by intervention." data-id="CD000039-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 1 Death or dependency, end of trial by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 2 Death or dependency, end of trial by stroke type." data-id="CD000039-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 2 Death or dependency, end of trial by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 3 Death or dependency, end of trial by stroke location." data-id="CD000039-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 3 Death or dependency, end of trial by stroke location. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 4 Death or dependency, end of trial by time to treatment." data-id="CD000039-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 4 Death or dependency, end of trial by time to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 5 Death, early by intervention." data-id="CD000039-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 5 Death, early by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 6 Death, early by stroke type." data-id="CD000039-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 6 Death, early by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 7 Death, early by time to treatment." data-id="CD000039-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 7 Death, early by time to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 8 Death, end of trial by intervention." data-id="CD000039-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 8 Death, end of trial by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 9 Death, end of trial by stroke type." data-id="CD000039-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 9 Death, end of trial by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 10 Death, end of trial by time to treatment." data-id="CD000039-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 10 Death, end of trial by time to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 11 Barthel Index, end of trial, by intervention." data-id="CD000039-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 11 Barthel Index, end of trial, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 12 Barthel Index, end of trial, by stroke type." data-id="CD000039-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 12 Barthel Index, end of trial, by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 13 Barthel Index, end of trial, by time to treatment." data-id="CD000039-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 13 Barthel Index, end of trial, by time to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 14 Early neurological deterioration, by intervention." data-id="CD000039-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 14 Early neurological deterioration, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 15 Early neurological deterioration, by stroke type." data-id="CD000039-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 15 Early neurological deterioration, by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 16 Early neurological deterioration, by time to treatment." data-id="CD000039-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 16 Early neurological deterioration, by time to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 17 Quality of life (EuroQol) at end of trial, by intervention." data-id="CD000039-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 17 Quality of life (EuroQol) at end of trial, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 18 Quality of life (EuroQoL) at end of trial, by stroke type." data-id="CD000039-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 18 Quality of life (EuroQoL) at end of trial, by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 19 Quality of life (EuroQoL) at end of trial, by time to treatment." data-id="CD000039-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 19 Quality of life (EuroQoL) at end of trial, by time to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 20 Length of stay, by intervention." data-id="CD000039-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 20 Length of stay, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 21 Length of stay, by stroke type." data-id="CD000039-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 21 Length of stay, by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 22 Length of stay, by time to treatment." data-id="CD000039-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 22 Length of stay, by time to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-23.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 23 SBP, first after randomisation, by intervention." data-id="CD000039-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 23 SBP, first after randomisation, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 24 SBP, first after randomisation by stroke type." data-id="CD000039-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 24 SBP, first after randomisation by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 25 SBP, first after randomisation by time to treatment." data-id="CD000039-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 25 SBP, first after randomisation by time to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 26 SBP, at day 1." data-id="CD000039-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 26 SBP, at day 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 27 SBP, at day 7." data-id="CD000039-fig-0030" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 27 SBP, at day 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 28 SBP, at end of treatment." data-id="CD000039-fig-0031" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 28 SBP, at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 29 DBP, first after randomisation by intervention." data-id="CD000039-fig-0032" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 29 DBP, first after randomisation by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 30 DBP, first after randomisation by stroke type." data-id="CD000039-fig-0033" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 30 DBP, first after randomisation by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 31 DBP, first after randomisation by time to treatment." data-id="CD000039-fig-0034" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 31 DBP, first after randomisation by time to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 32 DBP, at day 1." data-id="CD000039-fig-0035" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 32 DBP, at day 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 33 DBP, at day 7." data-id="CD000039-fig-0036" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 33 DBP, at day 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 34 DBP, at end of treatment." data-id="CD000039-fig-0037" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 34 DBP, at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 35 HR at baseline." data-id="CD000039-fig-0038" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 35 HR at baseline.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 36 HR, first after randomisation." data-id="CD000039-fig-0039" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 36 HR, first after randomisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 37 HR, at day 1." data-id="CD000039-fig-0040" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 37 HR, at day 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 38 HR, at day 7." data-id="CD000039-fig-0041" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 38 HR, at day 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-001-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-001-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 39 HR, at end of treatment." data-id="CD000039-fig-0042" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1 Blood pressure lowering therapy in acute stroke, Outcome 39 HR, at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-001-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 1 Death or dependency, end of trial by C/S." data-id="CD000039-fig-0043" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 1 Death or dependency, end of trial by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 2 Death or dependency, end of trial by stroke type C/S." data-id="CD000039-fig-0044" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 2 Death or dependency, end of trial by stroke type C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 3 Death or dependency, end of trial by time to treatment." data-id="CD000039-fig-0045" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 3 Death or dependency, end of trial by time to treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 4 Death early, by C/S." data-id="CD000039-fig-0046" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 4 Death early, by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 5 Death early, by stroke type C/S." data-id="CD000039-fig-0047" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 5 Death early, by stroke type C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 6 Death early, by time to treatment C/S." data-id="CD000039-fig-0048" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 6 Death early, by time to treatment C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 7 Death, end of trial by C/S." data-id="CD000039-fig-0049" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 7 Death, end of trial by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 8 Death end of trial, by stroke type C/S." data-id="CD000039-fig-0050" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 8 Death end of trial, by stroke type C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 9 Death, end of trial by time to treatment C/S." data-id="CD000039-fig-0051" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 9 Death, end of trial by time to treatment C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 10 Barthel Index, end of trial, by C/S." data-id="CD000039-fig-0052" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 10 Barthel Index, end of trial, by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 11 Early neurological deterioration, by C/S." data-id="CD000039-fig-0053" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 11 Early neurological deterioration, by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 12 Quality of life (EuroQol) at end of trial, by C/S." data-id="CD000039-fig-0054" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 12 Quality of life (EuroQol) at end of trial, by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 13 Length of stay, by C/S." data-id="CD000039-fig-0055" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 13 Length of stay, by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 14 SBP, first after randomisation, by C/S." data-id="CD000039-fig-0056" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 14 SBP, first after randomisation, by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 15 SBP, at day 1 by C/S." data-id="CD000039-fig-0057" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 15 SBP, at day 1 by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 16 SBP, at end of treatment by C/S." data-id="CD000039-fig-0058" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 16 SBP, at end of treatment by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 17 DBP, at baseline by C/S." data-id="CD000039-fig-0059" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 17 DBP, at baseline by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 18 DBP at day 1, by C/S." data-id="CD000039-fig-0060" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 18 DBP at day 1, by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 19 DBP, at end of treatment by C/S." data-id="CD000039-fig-0061" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 19 DBP, at end of treatment by C/S. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 20 HR, at day 1." data-id="CD000039-fig-0062" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 20 HR, at day 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 21 HR, at end of treatment." data-id="CD000039-fig-0063" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Blood pressure altering by continue or stop prestroke antihypertensives (C/S), Outcome 21 HR, at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 1 Death early, by intervention." data-id="CD000039-fig-0064" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 1 Death early, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 2 Death early, by stroke type." data-id="CD000039-fig-0065" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 2 Death early, by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 3 Death end of trial, by intervention." data-id="CD000039-fig-0066" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 3 Death end of trial, by intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 4 SBP, at baseline." data-id="CD000039-fig-0067" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 4 SBP, at baseline.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 5 SBP, first after randomisation." data-id="CD000039-fig-0068" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 5 SBP, first after randomisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 6 SBP, at day 1." data-id="CD000039-fig-0069" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 6 SBP, at day 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 7 DBP, at baseline." data-id="CD000039-fig-0070" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 7 DBP, at baseline.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 8 DBP, first after randomisation." data-id="CD000039-fig-0071" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 8 DBP, first after randomisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000039-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/urn:x-wiley:14651858:media:CD000039:CD000039-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_t/tCD000039-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 9 DBP, at day 1." data-id="CD000039-fig-0072" src="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Blood pressure elevation therapy in acute stroke, Outcome 9 DBP, at day 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/media/CDSR/CD000039/image_n/nCD000039-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD000039-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Blood pressure changes after first dose</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trials</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% CI</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2 %</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DBP</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% CI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACE‐I, oral</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.0 to ‐7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.7 to 1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACE‐I, sublingual</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐17.6 to 5.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+2.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.5 to 9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3408</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐8 to ‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.3 to ‐0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>α‐2 adrenoceptor agonist</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐41.5 to 14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐15.4 to 11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ß‐receptor antagonist, oral</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.3 to ‐2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13 to 2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ß‐receptor antagonist, iv</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐27.4 to ‐5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐17.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐25.3 to ‐9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, oral</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐17.2 to 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.3 to 2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, iv</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐24.4 to 4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐12.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐31.4 to 5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitric oxide donor</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4192</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐14.5 to ‐4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.4 to ‐2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diuretic, thiazide‐like</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐38.6 to ‐1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low BP target</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7421</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐15.3 to ‐7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐15.7 to 1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15432</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13.7, ‐8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.4 to ‐2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>ACE‐I: angiotensin converting enzyme inhibitors<br/> ARA: angiotensin receptor antagonist<br/> BP: blood pressure<br/> DBP: diastolic blood pressure<br/> SBP: systolic blood pressure<br/> iv: intravenous </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Blood pressure changes after first dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000039-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood pressure changes by type of intervention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACE‐I, oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐21.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACE‐I, sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Angiotensin receptor antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alpha‐2 adrenoceptor agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐21.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta‐receptor antagonist, oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta‐receptor antagonist, iv</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐13.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐31.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diuretic, thiazide‐like</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>ACE‐I: angiotensin converting enzyme inhibitors<br/> BP: blood pressure<br/> SBP: systolic blood pressure<br/> iv: intravenous </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood pressure changes by type of intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000039-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Heart rate changes at day 1</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type of intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Day 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95% CI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACE (oral)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐40.4 to 40.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alpha‐2 adrenoceptor agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.7 to 2.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blocker, iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐16.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐27.4 to ‐6.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 to 7.6</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ACE: angiotensin converting enzyme <br/> iv: intravenous </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Heart rate changes at day 1</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/full#CD000039-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000039-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Blood pressure lowering therapy in acute stroke</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death or dependency, end of trial by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.53, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 ARA(po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.93, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.42, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.86, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.86, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death or dependency, end of trial by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Combined Ischaemic stroke and Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.64, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Death or dependency, end of trial by stroke location <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Intracerebral haemorrhage, deep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.73, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Intracerebral haemorrhage, superficial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.77, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Ischaemic stroke, cortical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Ischaemic stroke, subcortical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Death or dependency, end of trial by time to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Ultra‐acute/pre‐hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.09, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Hyper‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10440</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Subacute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.84, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Death, early by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.74, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 ACE inhibitors (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.06, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 ARA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.05, 3.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.02, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Calcium channel blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.17, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Calcium channel blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [0.10, 73.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.37, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.66, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Death, early by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.76, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8844</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.73, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Combined ischaemic stroke and intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.25, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.61, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Death, early by time to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Ultra‐acute/prehospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.09, 14.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Hyper‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.59, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.78, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Subacute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.11, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Death, end of trial by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 ACE inhibitors (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.15, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 ARA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.59, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.17, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.72, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.87, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Death, end of trial by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Combined ischaemic stroke and intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.29, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Death, end of trial by time to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.75, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Ultra‐acute/pre‐hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.11, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Hyper‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.38, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Subacute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.39, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Barthel Index, end of trial, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [‐3.28, 4.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 ARA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐6.46, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐0.20, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Barthel Index, end of trial, by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [‐1.04, 3.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [‐3.21, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐5.18, 6.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Barthel Index, end of trial, by time to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.43 [‐14.19, 3.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Ultra‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.0 [‐25.66, ‐10.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐2.64, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Early neurological deterioration, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.92, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.30, 8.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.03, 8.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.66, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.80, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Early neurological deterioration, by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.09, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Combined ischaemic stroke and intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.31, 4.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Early neurological deterioration, by time to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.87, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Ultra‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.13, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Hyper‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.77, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.07, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Quality of life (EuroQol) at end of trial, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.01, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.02, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Quality of life (EuroQoL) at end of trial, by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.01, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.14, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.03, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Quality of life (EuroQoL) at end of trial, by time to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.00, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Ultra‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.07, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Hyperacute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.03, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Length of stay, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.30, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐2.11, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐1.76, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐1.76, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.31, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Length of stay, by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.30, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.33, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Combined ischaemic and Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐1.20, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [‐1.49, 6.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Length of stay, by time to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.30, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Ultra‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.88 [‐6.58, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.29, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 SBP, first after randomisation, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.83 [‐12.11, ‐7.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 ACE inhibitors(po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.68 [‐20.03, ‐7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 ACE inhibitors (s/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐17.55, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 ARA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.59 [‐7.71, ‐1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 A2AA(po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.67 [‐41.48, 14.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.5 Beta‐blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.5 [‐20.29, ‐2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.6 Beta‐blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.40 [‐27.40, ‐5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.7 Calcium channel blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.62 [‐17.21, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.8 Calcium channel blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.76 [‐24.42, 4.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.9 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.25 [‐14.54, ‐3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.10 Thiazide‐like diuretic (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.0 [‐38.60, ‐1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.11 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.39 [‐15.30, ‐7.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 SBP, first after randomisation by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.77 [‐11.04, ‐6.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.99 [‐8.61, ‐5.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Combined ischaemic stroke and intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.89 [‐12.43, ‐3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.77 [‐15.25, ‐8.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 SBP, first after randomisation by time to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.67 [‐12.14, ‐7.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Ultra‐acute/prehospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.98 [‐30.43, ‐1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Hyper‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.38 [‐15.41, ‐11.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.23 [‐9.83, ‐4.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.4 Subacute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.26 [‐10.02, ‐4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 SBP, at day 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.33 [‐10.97, ‐5.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 ACE inhibitors (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.90 [‐16.83, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 ACE inhibitors (s/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.0 [‐25.60, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 ARA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.52, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.4 A2AA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.83 [‐66.12, 22.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.5 Beta‐blockers(po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.00 [‐27.28, ‐0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.6 Beta‐blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐18.44, 8.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.7 Calcium channel blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.23 [‐43.36, 16.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.8 Calcium channel blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐31.90 [‐64.73, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.9 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.10 [‐19.06, ‐5.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.10 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.04 [‐12.47, ‐7.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 SBP, at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.74 [‐9.39, ‐4.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐26.0 [‐43.00, ‐7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 ARA(po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.74 [‐7.44, ‐4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 Thiazide‐like diuretic (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.0 [‐34.25, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.4 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.16 [‐2.63, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.5 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.62 [‐11.69, ‐3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 SBP, at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.02 [‐10.07, ‐5.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 ACE inhibitors (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐17.37 [‐23.42, ‐11.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 ACE inhibitors (s/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.5 [‐12.20, 9.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3 ARA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.37 [‐10.19, ‐4.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.4 A2AA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.5 Beta‐blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐13.17, 6.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.6 Beta‐blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.00 [‐25.21, ‐4.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.7 Calcium channel blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.80 [‐17.12, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.8 Calcium channel blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.20 [‐25.73, 7.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.9 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.05 [‐2.50, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.10 Thiazide‐like diuretic (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [‐11.74, 17.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.11 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.06 [‐13.58, ‐6.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 DBP, first after randomisation by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.86 [‐5.07, ‐2.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 ACE inhibitors(po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.23 [‐9.68, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 ACE inhibitors (s/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐5.50, 9.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3 ARA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.48 [‐4.35, ‐0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.4 A2AA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐15.43, 11.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.5 Beta‐Blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.40 [‐13.01, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.6 Beta‐Blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐17.5 [‐25.32, ‐9.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.7 Calcium channel blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐9.28, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.8 Calcium channel blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.90 [‐31.35, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.9 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.39 [‐4.25, ‐2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.10 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.43 [‐12.10, ‐0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 DBP, first after randomisation by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.73 [‐4.69, ‐2.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.53 [‐4.20, ‐2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 Combined ischaemic stroke and Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.85 [‐4.26, ‐1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.80 [‐11.99, ‐1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 DBP, first after randomisation by time to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐5.06, ‐2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 Ultra‐acute/prehospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [‐7.71, 10.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 Hyper‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.48 [‐12.55, ‐0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.3 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.11 [‐4.26, ‐1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.4 Subacute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.88 [‐7.98, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 DBP, at day 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.05 [‐4.20, ‐1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 ACE inhibitors (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.24 [‐8.95, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 ACE inhibitors (s/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐9.70, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.3 ARA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐3.47, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.4 A2AA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐26.77, 27.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.5 Beta‐blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐8.99, 6.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.6 Beta‐blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐13.21, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.7 Calcium channel blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.10 [‐14.08, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.8 Calcium channel blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.90 [‐31.35, 5.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.9 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.31 [‐4.17, ‐2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.10 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.34 [‐9.02, ‐1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 DBP, at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐3.96, ‐1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.0 [‐33.10, ‐2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 ARA(po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.47 [‐3.24, ‐1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐2.00, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.4 Thiazide‐like diuretic (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐16.00, 6.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.5 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.49 [‐6.18, ‐2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 DBP, at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.95 [‐5.15, ‐2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 ACE inhibitors (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.06 [‐11.18, ‐0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 ARA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.61 [‐5.61, ‐1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.3 ACE inhibitors (s/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐7.70, 7.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.4 Beta‐blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐7.48, 9.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.5 Beta‐Blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.40 [‐24.22, ‐8.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.6 Calcium channel blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.40 [‐15.50, ‐3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.7 Calcium channel blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐21.35, 15.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.8 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐2.00, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.9 Thiazide‐like diuretic (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐13.03, 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.10 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.24 [‐5.62, ‐2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 HR at baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.86, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 ACE inhibitors (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [‐5.31, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 ARA(po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐1.57, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.3 A2AA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.4 Calcium channel blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐9.47, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.5 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [‐1.26, 5.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.6 Thiazide‐like diuretic (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐10.50, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.7 Calcium channel blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.30 [‐4.21, 14.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.8 Low BP target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.0 [‐10.53, 4.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 HR, first after randomisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [‐1.13, 6.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 ACE inhibitors (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐9.89, 8.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 ARA(po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.3 Calcium channel blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [‐21.89, 24.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.4 A2AA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.5 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.95 [‐1.03, 8.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.6 Calcium channel blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.0 [0.71, 19.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 HR, at day 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [‐1.06, 5.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 ACE inhibitors (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐40.45, 40.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.2 Calcium channel blockers (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.56 [‐7.71, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.3 A2AA (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.4 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.53 [1.46, 7.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.5 Calcium channel blockers (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.90 [‐27.35, ‐6.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 HR, at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐0.24, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 Thiazide‐like diuretic (po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐6.14, 6.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 ARA(po)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐1.07, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.3 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [‐0.20, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 HR, at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐0.21, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [‐62.22, 67.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2 Thiazide‐ like diuretic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐6.14, 6.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.3 Nitric oxide donor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [‐0.20, 1.63]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Blood pressure lowering therapy in acute stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000039-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Blood pressure altering by continue or stop prestroke antihypertensives (C/S)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death or dependency, end of trial by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death or dependency, end of trial by stroke type C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.87, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Combined ischaemic stroke and intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.82, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.55, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Death or dependency, end of trial by time to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Ultra‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.69, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.89, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Death early, by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.55, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Death early, by stroke type C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.56, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.79, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Combined ischaemic stroke and intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.17, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.09, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Death early, by time to treatment C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.60, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Ultra‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.68 [0.27, 120.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.61, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Death, end of trial by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.92, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Death end of trial, by stroke type C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.94, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.96, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Combined ischaemic stroke and intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.67, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Intracerebral haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.45, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Death, end of trial by time to treatment C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.92, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Ultra‐acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.68, 5.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Acute</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.89, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Barthel Index, end of trial, by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.18 [‐5.80, ‐0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Early neurological deterioration, by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.89, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Quality of life (EuroQol) at end of trial, by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.05, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Length of stay, by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐0.87, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 SBP, first after randomisation, by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.11 [‐4.75, ‐1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 SBP, at day 1 by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.11 [‐4.75, ‐1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 SBP, at end of treatment by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.30 [‐15.20, ‐7.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 DBP, at baseline by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐1.65, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 DBP at day 1, by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.16 [‐2.24, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 DBP, at end of treatment by C/S <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.45 [‐9.28, ‐3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 HR, at day 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐0.70, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 HR, at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐4.51, ‐1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Blood pressure altering by continue or stop prestroke antihypertensives (C/S)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000039-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Blood pressure elevation therapy in acute stroke</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death early, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Phenylephrine (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death early, by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Death end of trial, by intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Phenylephrine (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 SBP, at baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.5 [‐50.83, ‐4.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Phenylephrine (iv)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.5 [‐50.83, ‐4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 SBP, first after randomisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.60 [‐13.31, 54.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 SBP, at day 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.60 [‐13.31, 54.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 DBP, at baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.30 [‐19.13, 2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 DBP, first after randomisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐14.86, 15.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 DBP, at day 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐14.86, 15.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Blood pressure elevation therapy in acute stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000039.pub3/references#CD000039-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000039.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000039-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000039-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000039-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD000039-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD000039-note-0006">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD000039-note-0002">한국어</a> </li> <li class="section-language"> <a class="" href="ru#CD000039-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000039\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000039\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000039\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000039\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000039\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000039.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000039.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000039.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000039.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000039.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714653755"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000039.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714653759"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000039.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d73f2fc37937f',t:'MTc0MDcxNDY1NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 